<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open-access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 2?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">4866775</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0155127</article-id><article-id pub-id-type="publisher-id">PONE-D-16-03205</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Pelvis</subject><subj-group><subject>Hip</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Musculoskeletal System</subject><subj-group><subject>Pelvis</subject><subj-group><subject>Hip</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Bacteria</subject><subj-group><subject>Actinobacteria</subject><subj-group><subject>Mycobacterium Tuberculosis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Computational Biology</subject><subj-group><subject>Genome Analysis</subject><subj-group><subject>Transcriptome Analysis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Genomics</subject><subj-group><subject>Genome Analysis</subject><subj-group><subject>Transcriptome Analysis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject><subj-group><subject>Gene Regulation</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Bacteriology</subject><subj-group><subject>Bacterial Genetics</subject><subj-group><subject>Toxin-Antitoxin Modules</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Microbial Genetics</subject><subj-group><subject>Bacterial Genetics</subject><subj-group><subject>Toxin-Antitoxin Modules</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Bacteriology</subject><subj-group><subject>Bacterial Physiology</subject><subj-group><subject>Toxin-Antitoxin Modules</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Physiology</subject><subj-group><subject>Bacterial Physiology</subject><subj-group><subject>Toxin-Antitoxin Modules</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject><subj-group><subject>Bacterial Toxins</subject><subj-group><subject>Toxin-Antitoxin Modules</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Toxicology</subject><subj-group><subject>Toxic Agents</subject><subj-group><subject>Toxins</subject><subj-group><subject>Bacterial Toxins</subject><subj-group><subject>Toxin-Antitoxin Modules</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene Expression</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Mutation</subject><subj-group><subject>Mutant Strains</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>High Persister Mutants in <italic>Mycobacterium tuberculosis</italic></article-title><alt-title alt-title-type="running-head">Hip Mutants in <italic>Mycobacterium tuberculosis</italic></alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Torrey</surname><given-names>Heather L.</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Keren</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Via</surname><given-names>Laura E.</given-names></name><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jong Seok</given-names></name><xref ref-type="aff" rid="aff003"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Lewis</surname><given-names>Kim</given-names></name><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Biology, Northeastern University, Boston, Massachusetts, United States of America</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America</addr-line></aff><aff id="aff003"><label>3</label><addr-line>International Tuberculosis Research Center, Changwon, Republic of Korea</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Kaufmann</surname><given-names>Gunnar F</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>The Scripps Research Institute and Sorrento Therapeutics, Inc., UNITED STATES</addr-line></aff><author-notes><fn fn-type="conflict" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con" id="contrib001"><p>Conceived and designed the experiments: HLT IK KL. Performed the experiments: HLT. Analyzed the data: HLT IK KL. Contributed reagents/materials/analysis tools: LEV JSL KL. Wrote the paper: HLT KL.</p></fn><corresp id="cor001">* E-mail: <email>k.lewis@neu.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><issue>5</issue><elocation-id>e0155127</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2016</year></date></history><permissions><license xlink:href="https://creativecommons.org/publicdomain/zero/1.0/"><license-p>This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">Creative Commons CC0</ext-link> public domain dedication.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0155127.pdf"/><abstract><p><italic>Mycobacterium tuberculosis</italic> forms drug-tolerant persister cells that are the probable cause of its recalcitrance to antibiotic therapy. While genetically identical to the rest of the population, persisters are dormant, which protects them from killing by bactericidal antibiotics. The mechanism of persister formation in <italic>M</italic>. <italic>tuberculosis</italic> is not well understood. In this study, we selected for high persister (<italic>hip</italic>) mutants and characterized them by whole genome sequencing and transcriptome analysis. In parallel, we identified and characterized clinical isolates that naturally produce high levels of persisters. We compared the <italic>hip</italic> mutants obtained <italic>in vitro</italic> with clinical isolates to identify candidate persister genes. Genes involved in lipid biosynthesis, carbon metabolism, toxin-antitoxin systems, and transcriptional regulators were among those identified. We also found that clinical <italic>hip</italic> isolates exhibited greater <italic>ex vivo</italic> survival than the low persister isolates. Our data suggest that <italic>M</italic>. <italic>tuberculosis</italic> persister formation involves multiple pathways, and <italic>hip</italic> mutants may contribute to the recalcitrance of the infection.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>Transformative Award T-R01AI085585</award-id><principal-award-recipient><name><surname>Lewis</surname><given-names>Kim</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100006492</institution-id><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>Contract No.:HHSN272200900018C</award-id><principal-award-recipient><name><surname>Via</surname><given-names>Laura E.</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution>Korean Centers for Disease Control of the Korean Ministry of Health and Welfare</institution></funding-source><principal-award-recipient><name><surname>Lee</surname><given-names>Jong Seok</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000865</institution-id><institution>Bill and Melinda Gates Foundation</institution></institution-wrap></funding-source><award-id>Grand Challenges</award-id><principal-award-recipient><name><surname>Lewis</surname><given-names>Kim</given-names></name></principal-award-recipient></award-group><funding-statement>This study was supported by the National Institutes of Health (NIH) Transformative Award T-R01AI085585 and Bill &#x00026; Melinda Gates Foundation Grand Challenges award to KL; by National Institute of Allergy and Infectious Diseases (NIAID), NIH, Department of Health and Human Services, under Contract No.:HHSN272200900018C. The clinical study and sample collection and analysis was jointly funded by Intramural Research Program of NIAID and the Korean Centers for Disease Control of the Korean Ministry of Health and Welfare including support of LEV and JSL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="6"/><table-count count="2"/><page-count count="28"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All files are available from the National Center for Biotechnology Information's Sequence Read Archive under BioProject PRJNA38649 and Gene Expression Omnibus under accession numbers GSE55647 and GSE62025.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All files are available from the National Center for Biotechnology Information's Sequence Read Archive under BioProject PRJNA38649 and Gene Expression Omnibus under accession numbers GSE55647 and GSE62025.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Over one third of the global human population is infected with <italic>Mycobacterium tuberculosis</italic>, the etiological agent of tuberculosis [<xref rid="pone.0155127.ref001" ref-type="bibr">1</xref>]. While up to 90% of tuberculosis infections are latent, with no clinical symptoms, they remain a concern due to their potential for reactivation [<xref rid="pone.0155127.ref002" ref-type="bibr">2</xref>], [<xref rid="pone.0155127.ref003" ref-type="bibr">3</xref>]. Treatment of active tuberculosis requires at least six months of antibiotic therapy. This lengthy treatment as well as the vast reservoir of latent infection is likely due to the presence of persister cells [<xref rid="pone.0155127.ref004" ref-type="bibr">4</xref>].</p><p>Persisters form a subpopulation of phenotypically drug tolerant cells. Unlike resistant mutants, persisters do not grow in the presence of antibiotics. Upon regrowth, persisters reestablish a population that retains the same susceptibility as the original population [<xref rid="pone.0155127.ref005" ref-type="bibr">5</xref>]. Persisters are produced by all bacterial species studied to date, but much of what we know about them is based on studies of <italic>Escherichia coli</italic>. Persisters are non-growing cells [<xref rid="pone.0155127.ref006" ref-type="bibr">6</xref>] whose gene expression profile [<xref rid="pone.0155127.ref007" ref-type="bibr">7</xref>] and low levels of translation [<xref rid="pone.0155127.ref008" ref-type="bibr">8</xref>] indicate that they are in a dormant state. The target pathways of antibiotics are inactive in dormant cells, which accounts for their tolerance to drug exposure [<xref rid="pone.0155127.ref008" ref-type="bibr">8</xref>]. In <italic>E</italic>. <italic>coli</italic>, pathways leading to dormancy are highly redundant and largely depend on the action of toxin-antitoxin (TA) modules [<xref rid="pone.0155127.ref007" ref-type="bibr">7</xref>], [<xref rid="pone.0155127.ref009" ref-type="bibr">9</xref>]. For example, protein synthesis inhibition by the HipA toxin [<xref rid="pone.0155127.ref010" ref-type="bibr">10</xref>], [<xref rid="pone.0155127.ref011" ref-type="bibr">11</xref>], a kinase [<xref rid="pone.0155127.ref012" ref-type="bibr">12</xref>] and by at least 10 different mRNA endonucleases such as RelE, MazF and YafQ [<xref rid="pone.0155127.ref007" ref-type="bibr">7</xref>], [<xref rid="pone.0155127.ref009" ref-type="bibr">9</xref>], [<xref rid="pone.0155127.ref013" ref-type="bibr">13</xref>], [<xref rid="pone.0155127.ref014" ref-type="bibr">14</xref>] leads to dormancy. In addition, damage of DNA induces the SOS response and expression of the TisB toxin [<xref rid="pone.0155127.ref015" ref-type="bibr">15</xref>], an endogenous antimicrobial peptide [<xref rid="pone.0155127.ref016" ref-type="bibr">16</xref>] that causes persister formation by opening an ion channel that decreases the proton motive force and ATP levels leading to a dormant, drug-tolerant state [<xref rid="pone.0155127.ref017" ref-type="bibr">17</xref>]. Typically overexpression of a persister gene leads to shutdown of an important cellular function, which results in drug tolerant persisters. Apart from TA modules, additional genes have been implicated in persister formation in <italic>E</italic>. <italic>coli</italic> including those involved in glycerol and nucleotide metabolism as well as some global regulators [<xref rid="pone.0155127.ref018" ref-type="bibr">18</xref>], [<xref rid="pone.0155127.ref019" ref-type="bibr">19</xref>], [<xref rid="pone.0155127.ref020" ref-type="bibr">20</xref>].</p><p>Transcriptome analysis of <italic>M</italic>. <italic>tuberculosis</italic> persister cells highlighted a metabolic downshift and upregulation of TA modules that is consistent with that observed in <italic>E</italic>. <italic>coli</italic> [<xref rid="pone.0155127.ref007" ref-type="bibr">7</xref>], [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>]. In <italic>M</italic>. <italic>tuberculosis</italic>, there are close to 80 TA modules identified so far [<xref rid="pone.0155127.ref022" ref-type="bibr">22</xref>], [<xref rid="pone.0155127.ref023" ref-type="bibr">23</xref>], indicating a potential for an extremely high level of redundancy in mechanisms governing dormancy. Direct evidence of TA systems playing a role in drug tolerance of <italic>M</italic>. <italic>tuberculosis</italic> has been reported. Ectopic overexpression of three individual <italic>E</italic>. <italic>coli relE</italic> homologues (Rv1246c, Rv2866, Rv3358) was found to increase drug tolerance [<xref rid="pone.0155127.ref024" ref-type="bibr">24</xref>]. Interestingly, <italic>relE</italic> overexpression effects are drug and isoform specific, which suggests that more than one subpopulation of persisters exist. Other mechanisms responsible for differential antibiotic susceptibility of mycobacteria include asymmetrical growth during cell division [<xref rid="pone.0155127.ref025" ref-type="bibr">25</xref>], stochastic expression of genes affecting antimicrobial action such as catalase-peroxidase <italic>katG</italic>, which activates the prodrug isoniazid and affects drug tolerance in a subset of cells [<xref rid="pone.0155127.ref026" ref-type="bibr">26</xref>], and changes that affect storage lipid accumulation [<xref rid="pone.0155127.ref027" ref-type="bibr">27</xref>] such as shifts in carbon flux through the TCA cycle [<xref rid="pone.0155127.ref028" ref-type="bibr">28</xref>]. The latter points to alterations in metabolism as a key factor influencing drug tolerance in <italic>M</italic>. <italic>tuberculosis</italic>.</p><p>While a persister cell is in a temporary state, the proportion of persisters within a population is relatively stable. Typically, the frequency of persister formation increases with cell density and reaches about 1% in stationary phase [<xref rid="pone.0155127.ref005" ref-type="bibr">5</xref>], [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>], [<xref rid="pone.0155127.ref029" ref-type="bibr">29</xref>]. The frequency of persister formation can also change with mutations. For example in <italic>E</italic>. <italic>coli</italic>, a gain of function mutation in the HipA toxin, obtained through <italic>in vitro</italic> mutagenesis, increases the level of persister production 1,000-fold [<xref rid="pone.0155127.ref030" ref-type="bibr">30</xref>]. In <italic>Salmonella typhimurium</italic>, a high persister (<italic>hip</italic>) mutation in the RelB toxin also increases persister production over 1,000-fold [<xref rid="pone.0155127.ref031" ref-type="bibr">31</xref>]. Selection for <italic>hip</italic> mutants can also occur in a clinical setting. Antibiotic treatment has been shown to select for <italic>hip</italic> mutants in patients with <italic>Candida albicans</italic> biofilms [<xref rid="pone.0155127.ref032" ref-type="bibr">32</xref>] or with <italic>Pseudomonas aeruginosa</italic> infection [<xref rid="pone.0155127.ref033" ref-type="bibr">33</xref>]. In <italic>E</italic>. <italic>coli</italic>, gain of function HipA mutants were recently discovered in clinical isolates and shown to have increased levels of persisters in an <italic>ex vivo</italic> model of infection [<xref rid="pone.0155127.ref034" ref-type="bibr">34</xref>]. These findings link persisters to clinical manifestation of disease. To date no <italic>hip</italic> mutants of <italic>M</italic>. <italic>tuberculosis</italic> have been reported. Here we report identification of <italic>hip</italic> mutants of <italic>M</italic>. <italic>tuberculosis</italic> obtained from an <italic>in vitro</italic> selection, and from a screen of clinical isolates.</p></sec><sec sec-type="results" id="sec002"><title>Results</title><sec id="sec003"><title>Characterization of <italic>hip</italic> mutants obtained <italic>in vitro</italic></title><sec id="sec004"><title><italic>Hip</italic> phenotype selection</title><p>To identify genes responsible for persister formation, we mutagenized <italic>M</italic>. <italic>tuberculosis</italic> mc<sup>2</sup>6020, an auxotroph of H37Rv [<xref rid="pone.0155127.ref035" ref-type="bibr">35</xref>], and selected for mutants surviving treatment with a lethal dose of streptomycin and rifampicin. With each round of selection, the level of persisters surviving antibiotic treatment increased in both exponential and stationary phase (<xref ref-type="fig" rid="pone.0155127.g001">Fig 1A and 1B</xref>). Three representative mutant strains were characterized further. The strains produced 100- to 1,000-fold more persisters than the parental wild type strain (mc<sup>2</sup>6020) in time-dependent (<xref ref-type="fig" rid="pone.0155127.g001">Fig 1C and 1D</xref>) and concentration-dependent antibiotic treatment (<xref ref-type="fig" rid="pone.0155127.g001">Fig 1E and 1F</xref>). In addition, the mutants consistently produced significantly more (<italic>p</italic>-value &#x0003c; 0.05) persisters than the wild type (mc<sup>2</sup>6020) when treated with antibiotics belonging to different classes that were not used in the selection process (<xref ref-type="fig" rid="pone.0155127.g001">Fig 1G</xref>), and when grown on various carbon sources (glycerol, butyrate, and propionate) (<xref ref-type="fig" rid="pone.0155127.g001">Fig 1H</xref>). For each mutant, neither minimum inhibitory concentration (MIC) (<xref ref-type="supplementary-material" rid="pone.0155127.s009">S4 Table</xref>) nor growth rate (<xref ref-type="supplementary-material" rid="pone.0155127.s010">S5 Table</xref>) differed significantly from the wild type (mc<sup>2</sup>6020) (<italic>p</italic>-value &#x0003c; 0.05). These selection criteria ruled out the possibility that increased drug resistance or growth defects were responsible for increased survival. Taken together, these results show that the <italic>hip</italic> mutants selected <italic>in vitro</italic> are multidrug tolerant and that their phenotype is independent of antibiotic class, antibiotic concentration, growth phase, or carbon source.</p><fig id="pone.0155127.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.g001</object-id><label>Fig 1</label><caption><title>Characterization of <italic>hip</italic> mutants obtained <italic>in vitro</italic>.</title><p>Persister assays, performed by antibiotic treatment with streptomycin (10 &#x003bc;g/ml) and rifampicin (1 &#x003bc;g/ml) for 14 days, reveal the number of drug tolerant persister cells based on CFU counts. Exponential (A) and stationary phase (B) treatment of mutagenized strain mc<sup>2</sup>6020 at each stage of the <italic>hip</italic> mutant selection process. Time-dependent persister assays in exponential (C) and stationary phase (D) with independent mutants KL2801, KL2825, KL2849, and wild type strain (mc<sup>2</sup>6020). Late exponential phase cultures were treated with various concentrations of streptomycin (E) or rifampicin (F) or with antibiotics not used in the selection process, kanamycin (50 &#x003bc;g/ml) or ofloxacin (10 &#x003bc;g/ml) (G). Cultures grown in minimal media with glycerol, butyrate, or propionate as the sole carbon source were treated in exponential phase (H). Data represent the average of three biological replicates and the error bars represent standard deviation.</p></caption><graphic xlink:href="pone.0155127.g001"/></fig></sec><sec id="sec005"><title>Whole genome sequencing and transcriptome analysis to identify candidate genes</title><p>The genomes of 18 <italic>hip</italic> mutants derived from 12 independent mutageneses were sequenced by Illumina technology and found to carry between one and 16 non-synonymous mutations (<xref ref-type="fig" rid="pone.0155127.g002">Fig 2</xref> and <xref ref-type="table" rid="pone.0155127.t001">Table 1</xref>). In one case, three mutants derived from the same mutagenesis (KL2849, KL2850, KL2851) contained identical non-synonymous mutations while strains derived from independent mutageneses contained mostly unique mutations. Since gene expression information could help elucidate the potential involvement of a candidate gene in the <italic>hip</italic> phenotype, transcriptome analysis of stationary phase <italic>hip</italic> mutants was carried out (<xref ref-type="supplementary-material" rid="pone.0155127.s011">S6 Table</xref>). Interestingly, transcriptome analysis showed high similarity in gene expression in the three <italic>hip</italic> mutants (KL2801, KL2825, KL2849) (<xref ref-type="supplementary-material" rid="pone.0155127.s012">S7 Table</xref>) even though there was no overlap in non-synonymous mutations (<xref ref-type="table" rid="pone.0155127.t001">Table 1</xref>). This suggested that they each contained mutations in a common pathway. In KL2849, the single non-synonymous mutation in fatty-acid-CoA ligase <italic>fadD26</italic> (G74*) was an interesting candidate. <italic>FadD26</italic> is involved in biosynthesis of phthiocerol dimycocerosate (PDIM), an important virulence lipid. Subsequent total lipid analysis confirmed an absence of PDIM among the three strains (<xref ref-type="supplementary-material" rid="pone.0155127.s001">S1 Fig</xref>). With KL2801 and KL2825, while there was no mutation in the ORFs of its biosynthetic pathway, it is possible that a mutation in a promoter or regulatory region is responsible for the PDIM-null phenotype. Sequence analysis revealed multiple mutations and single non-synonymous mutations in genes associated with PDIM biosynthesis in several other <italic>hip</italic> mutants (<xref ref-type="table" rid="pone.0155127.t001">Table 1</xref>).</p><fig id="pone.0155127.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.g002</object-id><label>Fig 2</label><caption><title>Genetic analysis of <italic>hip</italic> mutants obtained <italic>in vitro</italic>.</title><p>Representative antibiotic survival plots of 18 <italic>hip</italic> mutant strains, obtained from 12 independent mutageneses, are presented along with lists of genes containing non-synonymous mutations within each strain.</p></caption><graphic xlink:href="pone.0155127.g002"/></fig><table-wrap id="pone.0155127.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.t001</object-id><label>Table 1</label><caption><title>Non-synonymous mutations identified in individual <italic>in vitro hip</italic> mutant strains by whole genome sequencing.</title></caption><alternatives><graphic id="pone.0155127.t001g" xlink:href="pone.0155127.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Strain</th><th align="left" rowspan="1" colspan="1">Gene</th><th align="left" rowspan="1" colspan="1">Annotation</th><th align="left" rowspan="1" colspan="1">Location</th><th align="left" rowspan="1" colspan="1">Reference</th><th align="left" rowspan="1" colspan="1">Mutant</th><th align="left" rowspan="1" colspan="1">Change</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">KL2801</td><td align="left" rowspan="1" colspan="1">Rv1387</td><td align="left" rowspan="1" colspan="1">PPE family protein</td><td align="right" rowspan="1" colspan="1">1563341</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P525S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv1395</td><td align="left" rowspan="1" colspan="1">transcriptional regulator</td><td align="right" rowspan="1" colspan="1">1571669</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P208L</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2071c</td><td align="left" rowspan="1" colspan="1">precorrin-4 c11-methyltransferase cobM</td><td align="right" rowspan="1" colspan="1">2328463</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A172V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2249c</td><td align="left" rowspan="1" colspan="1">glycerol-3-phosphate dehydrogenase glpD1</td><td align="right" rowspan="1" colspan="1">2523381</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">R471W</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2423</td><td align="left" rowspan="1" colspan="1">hypothetical protein</td><td align="right" rowspan="1" colspan="1">2719708</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">V38M</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2802</td><td align="left" rowspan="1" colspan="1">Rv0351</td><td align="left" rowspan="1" colspan="1">chaperone grpE</td><td align="right" rowspan="1" colspan="1">422212</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">M168I</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv1656</td><td align="left" rowspan="1" colspan="1">ornithine carbamoyltransferase argF</td><td align="right" rowspan="1" colspan="1">1870565</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A215V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv1702c</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">1927776</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G267D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2379c</td><td align="left" rowspan="1" colspan="1">peptide synthetase mbtF</td><td align="right" rowspan="1" colspan="1">2661260</td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1">F276L</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2933</td><td align="left" rowspan="1" colspan="1">phenolpthiocerol synthesis type-I polyketide synthase ppsC</td><td align="right" rowspan="1" colspan="1">3261616</td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1">W1978R</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2803</td><td align="left" rowspan="1" colspan="1">Rv1564c</td><td align="left" rowspan="1" colspan="1">maltooligosyltrehalose synthase treX</td><td align="right" rowspan="1" colspan="1">1769662</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A647V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv1576c</td><td align="left" rowspan="1" colspan="1">phiRv1 phage protein</td><td align="right" rowspan="1" colspan="1">1781577</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">T163I</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2825</td><td align="left" rowspan="1" colspan="1">Rv0254c</td><td align="left" rowspan="1" colspan="1">bifunctional cobalamin biosynthesis protein cobU</td><td align="right" rowspan="1" colspan="1">305878</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">A158T</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv3560c</td><td align="left" rowspan="1" colspan="1">acyl-CoA dehydrogenase fadE30</td><td align="right" rowspan="1" colspan="1">4000449</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">R381W</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2826</td><td align="left" rowspan="1" colspan="1">Rv1227c</td><td align="left" rowspan="1" colspan="1">transmembrane protein</td><td align="right" rowspan="1" colspan="1">1370665</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">W54*</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2307c</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2578588</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P37S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2368c</td><td align="left" rowspan="1" colspan="1">phosphate starvation-inducible protein phoH1</td><td align="right" rowspan="1" colspan="1">2649391</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">T195M</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2383c</td><td align="left" rowspan="1" colspan="1">phenyloxazoline synthase mbtB</td><td align="right" rowspan="1" colspan="1">2671835</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P1335S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2389c</td><td align="left" rowspan="1" colspan="1">resuscitation-promoting factor rpfD</td><td align="right" rowspan="1" colspan="1">2683423</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A97V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2428</td><td align="left" rowspan="1" colspan="1">alkyl hydroperoxide reductase C protein ahpC</td><td align="right" rowspan="1" colspan="1">2726541</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">E117K</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2442c</td><td align="left" rowspan="1" colspan="1">50S ribosomal protein L21 rplU</td><td align="right" rowspan="1" colspan="1">2740088</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">R92C</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2454c</td><td align="left" rowspan="1" colspan="1">oxidoreductase beta subunit</td><td align="right" rowspan="1" colspan="1">2754530</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P73S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2462c</td><td align="left" rowspan="1" colspan="1">trigger factor protein tig</td><td align="right" rowspan="1" colspan="1">2764088</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P402S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2482c</td><td align="left" rowspan="1" colspan="1">glycerol-3-phosphate acyltransferase plsB2</td><td align="right" rowspan="1" colspan="1">2788623</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">L221F</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2508c</td><td align="left" rowspan="1" colspan="1">conserved alanine and leucine rich membrane protein</td><td align="right" rowspan="1" colspan="1">2824394</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A67V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2516c</td><td align="left" rowspan="1" colspan="1">hypothetical protein</td><td align="right" rowspan="1" colspan="1">2832738</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A259V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2543</td><td align="left" rowspan="1" colspan="1">lipoprotein lppA</td><td align="right" rowspan="1" colspan="1">2866837</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">V124I</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2587c</td><td align="left" rowspan="1" colspan="1">protein-export membrane protein secD</td><td align="right" rowspan="1" colspan="1">2915001</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P246S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2930</td><td align="left" rowspan="1" colspan="1">fatty-acid-CoA ligase fadD26</td><td align="right" rowspan="1" colspan="1">3243916</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">G74*</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2946c</td><td align="left" rowspan="1" colspan="1">polyketide synthase pks1</td><td align="right" rowspan="1" colspan="1">3293047</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">E1103K</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2827</td><td align="left" rowspan="1" colspan="1">Rv2940c</td><td align="left" rowspan="1" colspan="1">multifunctional mycocerosic acid synthase membrane-associated mas</td><td align="right" rowspan="1" colspan="1">3280534</td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1">S728P</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2849</td><td align="left" rowspan="1" colspan="1">Rv2930</td><td align="left" rowspan="1" colspan="1">fatty-acid-CoA ligase fadD26</td><td align="right" rowspan="1" colspan="1">3243916</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">G74*</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2850</td><td align="left" rowspan="1" colspan="1">Rv2930</td><td align="left" rowspan="1" colspan="1">fatty-acid-CoA ligase fadD26</td><td align="right" rowspan="1" colspan="1">3243916</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">G74*</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2851</td><td align="left" rowspan="1" colspan="1">Rv2930</td><td align="left" rowspan="1" colspan="1">fatty-acid-CoA ligase fadD26</td><td align="right" rowspan="1" colspan="1">3243916</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">G74*</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1090</td><td align="left" rowspan="1" colspan="1">Rv2324</td><td align="left" rowspan="1" colspan="1">transcriptional regulator, asnC-family</td><td align="right" rowspan="1" colspan="1">2596356</td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1">D8G</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2933</td><td align="left" rowspan="1" colspan="1">phenolpthiocerol synthesis type-I polyketide synthase ppsC</td><td align="right" rowspan="1" colspan="1">3257052</td><td align="left" rowspan="1" colspan="1"><monospace>AC</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>AGACGAATGC&#x02026;</monospace></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">KL1105</td><td align="left" rowspan="1" colspan="1">Rv0282</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">342139</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">V4L</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2281</td><td align="left" rowspan="1" colspan="1">phosphate-transport permease pitB</td><td align="right" rowspan="1" colspan="1">2554762</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">W530*</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2324</td><td align="left" rowspan="1" colspan="1">transcriptional regulator, asnC-family</td><td align="right" rowspan="1" colspan="1">2596559</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G76S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2362c</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2643744</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">T172I</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2391</td><td align="left" rowspan="1" colspan="1">ferredoxin-dependent nitrite reductase nirA</td><td align="right" rowspan="1" colspan="1">2685163</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G162E</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2402</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2699244</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">W239*</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2425c</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2722000</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">L437F</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2933</td><td align="left" rowspan="1" colspan="1">phenolpthiocerol synthesis type-I polyketide synthase ppsC</td><td align="right" rowspan="1" colspan="1">3257052</td><td align="left" rowspan="1" colspan="1"><monospace>AC</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>AGACGAATGC&#x02026;</monospace></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">KL1116</td><td align="left" rowspan="1" colspan="1">Rv2324</td><td align="left" rowspan="1" colspan="1">transcriptional regulator, asnC-family</td><td align="right" rowspan="1" colspan="1">2596492</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">F52L</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv3696c</td><td align="left" rowspan="1" colspan="1">glycerol kinase glpK</td><td align="right" rowspan="1" colspan="1">4139183</td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>AC</monospace></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">KL1117</td><td align="left" rowspan="1" colspan="1">Rv1131</td><td align="left" rowspan="1" colspan="1">citrate synthase I gltA1</td><td align="right" rowspan="1" colspan="1">1257138</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G335E</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2324</td><td align="left" rowspan="1" colspan="1">transcriptional regulator, asnC-family</td><td align="right" rowspan="1" colspan="1">2596619</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A95S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2930</td><td align="left" rowspan="1" colspan="1">fatty-acid-CoA ligase fadD26</td><td align="right" rowspan="1" colspan="1">3244737</td><td align="left" rowspan="1" colspan="1"><monospace>CA</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">KL1120</td><td align="left" rowspan="1" colspan="1">Rv1791</td><td align="left" rowspan="1" colspan="1">PE family protein</td><td align="right" rowspan="1" colspan="1">2030036</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">D44N</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2182c</td><td align="left" rowspan="1" colspan="1">1-acylglycerol-3-phosphate o-acyltransferase</td><td align="right" rowspan="1" colspan="1">2445124</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G68D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2198c</td><td align="left" rowspan="1" colspan="1">membrane protein mmpS3</td><td align="right" rowspan="1" colspan="1">2462848</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G66D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2220</td><td align="left" rowspan="1" colspan="1">glutamine synthetase glnA1</td><td align="right" rowspan="1" colspan="1">2487928</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">S104F</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2254c</td><td align="left" rowspan="1" colspan="1">membrane protein</td><td align="right" rowspan="1" colspan="1">2528774</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">A67T</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2289</td><td align="left" rowspan="1" colspan="1">cdp-diacylglycerol pyrophosphatase cdh</td><td align="right" rowspan="1" colspan="1">2562042</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A122V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2934</td><td align="left" rowspan="1" colspan="1">phenolpthiocerol synthesis type-I polyketide synthase ppsD</td><td align="right" rowspan="1" colspan="1">3266422</td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1">L1391P</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1130</td><td align="left" rowspan="1" colspan="1">Rv2323c</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2596217</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">R17H</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1134</td><td align="left" rowspan="1" colspan="1">Rv1521</td><td align="left" rowspan="1" colspan="1">fatty-acid-CoA ligase fadD25</td><td align="right" rowspan="1" colspan="1">1713505</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G401R</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv1536</td><td align="left" rowspan="1" colspan="1">isoleucyl-tRNA synthetase ileS</td><td align="right" rowspan="1" colspan="1">1738703</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">E728K</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2184c</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2446234</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A237V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2211c</td><td align="left" rowspan="1" colspan="1">aminomethyltransferase gcvT</td><td align="right" rowspan="1" colspan="1">2476797</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P128S</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2245</td><td align="left" rowspan="1" colspan="1">3-oxoacyl-[acyl-carrier protein] synthase 1 kasA</td><td align="right" rowspan="1" colspan="1">2519289</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G391D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2263</td><td align="left" rowspan="1" colspan="1">oxidoreductase</td><td align="right" rowspan="1" colspan="1">2535777</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">R45H</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2308</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2580606</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G62D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2327</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">2600309</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">E107K</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2376c</td><td align="left" rowspan="1" colspan="1">low molecular weigKL protein antigen cfp2</td><td align="right" rowspan="1" colspan="1">2655937</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">A59V</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2934</td><td align="left" rowspan="1" colspan="1">phenolpthiocerol synthesis type-I polyketide synthase ppsD</td><td align="right" rowspan="1" colspan="1">3264484</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">A745E</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1137</td><td align="left" rowspan="1" colspan="1">Rv0192</td><td align="left" rowspan="1" colspan="1">conserved hypothetical protein</td><td align="right" rowspan="1" colspan="1">223958</td><td align="left" rowspan="1" colspan="1"><monospace>C</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>T</monospace></td><td align="left" rowspan="1" colspan="1">P131L</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv2931</td><td align="left" rowspan="1" colspan="1">phenolpthiocerol synthesis type-I polyketide synthase ppsA</td><td align="right" rowspan="1" colspan="1">3247786</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G780D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv3696c</td><td align="left" rowspan="1" colspan="1">glycerol kinase glpK</td><td align="right" rowspan="1" colspan="1">4138776</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G326D</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Rv3919c</td><td align="left" rowspan="1" colspan="1">glucose-inhibited division protein B gid</td><td align="right" rowspan="1" colspan="1">4407977</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">G75S</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1170</td><td align="left" rowspan="1" colspan="1">Rv3696c</td><td align="left" rowspan="1" colspan="1">glycerol kinase glpK</td><td align="right" rowspan="1" colspan="1">4138299</td><td align="left" rowspan="1" colspan="1"><monospace>G</monospace></td><td align="left" rowspan="1" colspan="1"><monospace>A</monospace></td><td align="left" rowspan="1" colspan="1">R485Q</td></tr></tbody></table></alternatives></table-wrap><p>To test whether the loss of PDIM is associated with the <italic>hip</italic> phenotype, we compared the growth-persister pattern of the <italic>fadD26</italic> (G74*) PDIM-null <italic>hip</italic> mutant (KL2849) and the parental wild type strain (mc<sup>2</sup>6020) with that of a previously published <italic>fadD26</italic> transposon (Tn) null mutant and its parental wild type strain (Erdman) [<xref rid="pone.0155127.ref036" ref-type="bibr">36</xref>]. While the backgrounds of the <italic>fadD26</italic>::Tn and <italic>hip</italic> mutant differ (H37Rv derivative versus Erdman), comparison is possible since a common role for PDIM has been reported in these two strains [<xref rid="pone.0155127.ref036" ref-type="bibr">36</xref>], [<xref rid="pone.0155127.ref037" ref-type="bibr">37</xref>]. In both cases, the PDIM mutant produced more persisters than its parental strain (<xref ref-type="fig" rid="pone.0155127.g003">Fig 3A and 3B</xref>). Interestingly, a PDIM-transport protein <italic>drrA</italic> (Rv2936) H37Rv mutant [<xref rid="pone.0155127.ref038" ref-type="bibr">38</xref>], which produces PDIM but does not correctly localize it to the cell wall, did not have a <italic>hip</italic> phenotype (<xref ref-type="supplementary-material" rid="pone.0155127.s002">S2 Fig</xref>). This suggests that it is the biosynthesis of PDIM, rather than the lipid itself, that is responsible for the difference in drug tolerance. We noticed that the <italic>fadD26</italic>::Tn mutant exhibited a faster growth rate than the wild type (Erdman) (<xref ref-type="fig" rid="pone.0155127.g003">Fig 3B</xref>). While there was no significant difference in growth rate of KL2849 compared to wild type (mc<sup>2</sup>6020), the <italic>hip</italic> mutant had a slightly shorter generation time during early exponential growth (<xref ref-type="supplementary-material" rid="pone.0155127.s010">S5 Table</xref>). Taken together, these results suggest that the absence of PDIM production gives PDIM-null mutants a growth advantage. Since persister formation is growth stage-dependent, the changes in PDIM production may indirectly affect antibiotic tolerance by changing the timing of transition from exponential to stationary phase.</p><fig id="pone.0155127.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.g003</object-id><label>Fig 3</label><caption><title>Growth and persister assays of <italic>fadD26</italic> PDIM mutant strains.</title><p>PDIM mutant strain KL2849 (<italic>fadD26</italic> G74*) and wild type (mc<sup>2</sup>6020) (A) or <italic>fadD26</italic>::Tn and wild type (Erdman) (B) were grown (solid lines) and treated with streptomycin (10 &#x003bc;g/ml) and rifampicin (1 &#x003bc;g/ml) at the indicated time points for 14 days (dashed lines). Bacterial survival was determined by plating for CFU. Growth curves were also monitored based on OD<sub>600</sub> readings. The values are an average of three biological replicates and error bars represent standard deviation.</p></caption><graphic xlink:href="pone.0155127.g003"/></fig><p>Genes and pathways that have previously been associated with persister formation were also of interest when analyzing the <italic>M</italic>. <italic>tuberculosis hip</italic> mutants. In <italic>E</italic>. <italic>coli</italic>, glycerol metabolism has been linked to persister formation [<xref rid="pone.0155127.ref018" ref-type="bibr">18</xref>], [<xref rid="pone.0155127.ref020" ref-type="bibr">20</xref>]. In the <italic>hip</italic> mutants, two confirmed <italic>E</italic>. <italic>coli</italic> persister gene candidates, glycerol-3-phosphate dehydrogenase <italic>glpD1</italic> (Rv2249c) and glycerol-3-phosphate acyltransferase <italic>plsB2</italic> (Rv2484c), were found to contain non-synonymous mutations. We tested whether overexpression of either <italic>glpD1</italic> or <italic>plsB2</italic>, confirmed by immunoblot, had an effect on persister formation but the results were negative (<xref ref-type="supplementary-material" rid="pone.0155127.s003">S3 Fig</xref>). There are several possible explanations for the lack of an effect on persisters by overexpression of these two genes. First, there are two copies of each of these genes in <italic>M</italic>. <italic>tuberculosis</italic>, which may provide functional genetic redundancy. Second, downregulation rather than overexpression may be required as in the case of <italic>plsB</italic> in <italic>E</italic>. <italic>coli</italic>. Both genes were significantly downregulated in various <italic>hip</italic> mutants, supporting this possibility (<xref ref-type="supplementary-material" rid="pone.0155127.s011">S6 Table</xref>). In addition to <italic>glpD1</italic> and <italic>plsB2</italic>, we found several mutations in glycerol kinase <italic>glpK</italic> (Rv3696c). In <italic>E</italic>. <italic>coli</italic>, a <italic>glpK</italic>-null mutant had no persister phenotype [<xref rid="pone.0155127.ref018" ref-type="bibr">18</xref>] therefore we did not pursue it further as a candidate. Genes involved in the TCA cycle have also been implicated in drug tolerance in <italic>M</italic>. <italic>tuberculosis</italic> [<xref rid="pone.0155127.ref028" ref-type="bibr">28</xref>], [<xref rid="pone.0155127.ref039" ref-type="bibr">39</xref>]. In the three representative <italic>hip</italic> mutants, isocitrate lyase <italic>icl</italic> (Rv0467) was significantly upregulated in stationary phase (<xref ref-type="supplementary-material" rid="pone.0155127.s012">S7 Table</xref>) while citrate synthase <italic>gltA1</italic> (Rv1131) contained a non-synonymous SNP and was upregulated in KL1117 (<xref ref-type="supplementary-material" rid="pone.0155127.s011">S6 Table</xref>).</p><p>We noted global changes in metabolism of the <italic>hip</italic> mutants by transcriptome analysis showing significant upregulation of genes associated with energy production, such as a possible oxidoreductase (Rv3742c), inorganic ion metabolism, such as rubredoxin <italic>rubA</italic> and <italic>rubB</italic> (Rv3250c-Rv3251c), and lactate dehydrogenase (Rv1872c) (<xref ref-type="supplementary-material" rid="pone.0155127.s013">S8 Table</xref>). Downregulation of two transcriptional regulators (Rv0273 and Rv3066) is of interest as they may control of the expression of multiple genes (<xref ref-type="supplementary-material" rid="pone.0155127.s013">S8 Table</xref>). Another candidate is probable asparagine synthase C <italic>asnC</italic> family transcriptional regulator (Rv2324). As a feast/famine regulatory protein, the <italic>asnC</italic> transcriptional regulator controls the expression of a large number of genes in response to stress or changes in the environment [<xref rid="pone.0155127.ref040" ref-type="bibr">40</xref>]. While there was no clear trend in differential expression of Rv2324 (<xref ref-type="supplementary-material" rid="pone.0155127.s011">S6 Table</xref>), multiple independent mutations occurred in the <italic>hip</italic> mutants in this gene as well as in the hypothetical protein (Rv2323c) directly upstream of it, which suggests an association with the <italic>hip</italic> phenotype.</p></sec></sec><sec id="sec006"><title>Characterization of clinical isolates with a <italic>hip</italic> phenotype</title><sec id="sec007"><title>Longitudinal clinical isolate analysis</title><p>Repeated exposure of a mutagenized population to high doses of antibiotics enabled us to select for <italic>hip</italic> mutants of <italic>M</italic>. <italic>tuberculosis in vitro</italic>. We reasoned that in a clinical setting repeated treatment of patients with high doses of antibiotics might also select for <italic>hip</italic> mutants. To examine this possibility, we assessed persister levels of matched pairs of isolates from four longitudinal clinical tuberculosis cases. In each case, due to relapse or treatment failure, the patient had been treated for an extended period (<xref ref-type="supplementary-material" rid="pone.0155127.s014">S9 Table</xref>). The early and late isolates were collected at least 24 months apart and the pairs were matched based on identical high-resolution (24-loci) mycobacterial interspersed repetitive unit&#x02014;variable number tandem repeat (MIRU-VNTR) genotyping patterns. Importantly, while some of the isolates were drug resistant (<xref ref-type="supplementary-material" rid="pone.0155127.s014">S9 Table</xref>), there was no change in MIC of the antibiotic used in the persister assay (<xref ref-type="supplementary-material" rid="pone.0155127.s015">S10 Table</xref>). To control for variation in growth rates among isolates, we performed the assay in stationary phase. When treated with kanamycin (125 &#x003bc;g/ml), one longitudinal pair (Case 3) exhibited a 10-fold increase in the level of persister formation from early to late (<xref ref-type="fig" rid="pone.0155127.g004">Fig 4A</xref>). This suggested that <italic>hip</italic> mutant selection could occur in clinical isolates of <italic>M</italic>. <italic>tuberculosis</italic>.</p><fig id="pone.0155127.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.g004</object-id><label>Fig 4</label><caption><title>Characterization of clinical isolates.</title><p>Longitudinal pairs of isolates from four cases of recalcitrant tuberculosis infection (A) or individual drug sensitive clinical isolates (B) were grown to stationary phase and treated with kanamycin (125 &#x003bc;g/ml) for 14 days and survival monitored by CFU counts. Genes containing non-synonymous SNPs differentiating the early and late isolate from Case 3 (C), unique to the four <italic>hip</italic> isolates (D), or unique the four low persister isolates (E) are presented. The values are an average of three biological replicates, error bars represent standard deviation, and stars represent significant difference (<italic>p</italic>-value &#x0003c; 0.001).</p></caption><graphic xlink:href="pone.0155127.g004"/></fig></sec><sec id="sec008"><title>Screen of independent, drug-sensitive clinical isolates</title><p>In the longitudinal study, we observed large variation in persister levels among independent isolates (<xref ref-type="fig" rid="pone.0155127.g004">Fig 4A</xref>), which further supported the possibility that <italic>hip</italic> strains exist among clinical isolates. To examine this possibility, we screened a large panel of 39 independent, drug-sensitive clinical isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s014">S9 Table</xref>). The isolates were all equally susceptible to the three antibiotics used in the persister assay (<xref ref-type="supplementary-material" rid="pone.0155127.s016">S11 Table</xref>). When treated in stationary phase with kanamycin (125 &#x003bc;g/ml), the level of persisters varied up to 10,000-fold among individual isolates (<xref ref-type="fig" rid="pone.0155127.g004">Fig 4B</xref>). Large variations in persister levels were also observed when the isolates were treated with moxifloxacin (20 &#x003bc;g/ml) or rifampicin (10 &#x003bc;g/ml) (<xref ref-type="supplementary-material" rid="pone.0155127.s004">S4 Fig</xref>). There was high correlation in isolate-specific persister level between kanamycin and moxifloxacin (r = 0.75, <italic>p</italic>-value &#x0003c; 0.01) but less correlation between kanamycin and rifampicin (r = 0.32, <italic>p</italic>-value &#x0003c; 0.05). To elucidate underlying genetic differences of strains that produce more persisters, we selected four high and low persister clinical isolates for further characterization.</p></sec><sec id="sec009"><title>Whole genome sequencing analysis of clinical isolates</title><p>Whole genome sequencing showed that the total number of non-synonymous SNPs between the clinical isolates and the reference strain (H37Rv) ranged from 156 to 854 with a mean of 709 per isolate (<xref ref-type="supplementary-material" rid="pone.0155127.s017">S12 Table</xref>). For the longitudinal pair of Case 3, we filtered the number of SNPs analyzed by eliminating any that occurred in Case 1, where there was no change in persister level (<xref ref-type="fig" rid="pone.0155127.g004">Fig 4C</xref> and <xref ref-type="supplementary-material" rid="pone.0155127.s018">S13 Table</xref>). Of the 28 non-synonymous SNPs identified, 23 occurred in proline-glutamate (PE) or proline-proline-glutamate (PPE) genes. Since PE/PPE genes are known to be highly variable in <italic>M</italic>. <italic>tuberculosis</italic>, we excluded them from further consideration as candidate genes involved in the <italic>hip</italic> phenotype. The remaining five included a glutamate transport transmembrane protein (Rv0072), a phosphate ABC transporter (Rv0933), and three hypothetical proteins (Rv0095c, Rv1879, and Rv2819c). For analysis of the panel of drug sensitive isolates, similar to our assessment of the <italic>hip</italic> mutants obtained <italic>in vitro</italic>, we looked for overlapping mutations. There were four identical non-synonymous SNPs that were unique to the <italic>hip</italic> isolates (<xref ref-type="fig" rid="pone.0155127.g004">Fig 4D</xref> and <xref ref-type="supplementary-material" rid="pone.0155127.s019">S14 Table</xref>). A possible maturase protein (Rv0071c) was the only non-PE/PPE gene that contained a common SNP in all four <italic>hip</italic> clinical isolates. There were no non-synonymous SNPs unique to all four low persister isolates, although one mutation in a PE/PPE gene (Rv0279c) occurred in three of them (<xref ref-type="fig" rid="pone.0155127.g004">Fig 4E</xref> and <xref ref-type="supplementary-material" rid="pone.0155127.s019">S14 Table</xref>). Next, we compared the high and low persister clinical isolates with the <italic>hip</italic> mutants obtained <italic>in vitro</italic>. Half of the 60 genes that possessed non-synonymous mutations in the <italic>in vitro hip</italic> mutants also contained mutations in the clinical isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s020">S15 Table</xref>). Of those 30 genes, 12 contained non-synonymous mutations that were specific to at least one <italic>hip</italic> clinical isolate including a transcriptional regulator (Rv1395), <italic>plsB2</italic> (Rv2482c), phenolphthiocerol synthesis type-1 polyketide synthase <italic>ppsD</italic> (Rv2933), and mycoserosic acid synthase <italic>mas</italic> (Rv2940c). This comprehensive genomic comparison of <italic>in vitro</italic> mutants and clinical isolates points to several novel candidate genes that may play a role in persister formation.</p></sec><sec id="sec010"><title>Transcriptome analysis of persister cells from clinical <italic>hip</italic> isolates</title><p>To further elucidate the differences between the clinical <italic>hip</italic> and low persister isolates, we compared their transcriptome profiles. We note that the <italic>in vitro</italic> transcriptome of clinical isolates could be different from their transcriptome during infection. At the same time, we reasoned that the genetic changes leading to a higher probability for producing persisters and that are observed <italic>in vitro</italic>, will similarly manifest themselves <italic>in vivo</italic>. The most straightforward way to isolate persisters <italic>in vitro</italic> is by lysing a growing culture with a cell wall synthesis inhibitor and collecting surviving persisters by centrifugation [<xref rid="pone.0155127.ref007" ref-type="bibr">7</xref>]. D-cycloserine is an effective cell-lysing antibiotic of <italic>M</italic>. <italic>tuberculosis</italic> [<xref rid="pone.0155127.ref041" ref-type="bibr">41</xref>] and has been successfully used to isolate persisters [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>]. Importantly, there was no difference in the D-cycloserine MIC among the eight clinical isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s016">S11 Table</xref>). The <italic>hip</italic> isolates, treated in mid-exponential phase (OD<sub>600</sub> 0.5) with D-cycloserine, produced more survivors than the low persister isolates (<xref ref-type="fig" rid="pone.0155127.g005">Fig 5A</xref>). The greatest difference between the <italic>hip</italic> and low persister isolates occurred at day 7 of treatment. We therefore collected samples at days 0 and 7 for transcriptome analysis. Comparative analysis between sample pairs of each isolate on day 0 and day 7 revealed that 13 genes were upregulated &#x0003e;4-fold in all four <italic>hip</italic> clinical isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s021">S16 Table</xref>). Three of these genes, including a transcriptional regulator (Rv2989), a hypothetical protein (Rv1291c), and an amino acid cysteine synthase (Rv0848), were uniquely upregulated in the <italic>hip</italic> isolates while the other 10 were upregulated &#x0003e;4-fold in all of the low persister isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s022">S17 Table</xref>). Upregulated genes in both groups include a heat shock protein (Rv0251c), catalase-peroxidase-peroxynitritase T <italic>katG</italic> (Rv1908c), <italic>gltA1</italic> (Rv1131), <italic>clpC2</italic> (Rv2667), and <italic>glpD1</italic> (Rv2249c). There were 16 genes downregulated &#x0003e;4-fold in all four <italic>hip</italic> isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s023">S18 Table</xref>). The majority of these showed significantly higher expression in the <italic>hip</italic> isolates compared to the low persister isolates at day 0 (representing the bulk population), prior to antibiotic treatment. In the low persister isolates, genes that were downregulated &#x0003e;4-fold included many of those identified in the <italic>hip</italic> isolates including two resuscitation-promoting factors, <italic>rpfC</italic> (Rv1884c) and <italic>rpfD</italic> (Rv2389c) (<xref ref-type="supplementary-material" rid="pone.0155127.s024">S19 Table</xref>). Comparative analysis of <italic>hip</italic> versus low persister isolates at day 0 and day 7 revealed genes that were upregulated &#x0003e;4-fold including triacylglycerol synthase <italic>tsg1</italic> (Rv3130c), the devRS two-component system (Rv3132c-Rv3133c) and cation-transporting ATPase (Rv3743c) (<xref ref-type="supplementary-material" rid="pone.0155127.s025">S20 Table</xref>). Interestingly, Rv3743c is involved in energy metabolism and is directly adjacent to the most upregulated gene identified in the <italic>in vitro hip</italic> mutants, Rv3742c (<xref ref-type="supplementary-material" rid="pone.0155127.s013">S8 Table</xref>).</p><fig id="pone.0155127.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.g005</object-id><label>Fig 5</label><caption><title>Antibiotic tolerance of <italic>hip</italic> and low persister clinical isolates.</title><p>Eight individual clinical isolates were grown exponential phase and treated with D-cycloserine (125 &#x003bc;g/ml) for 21 days and survival monitored by CFU counts (A). Macrophages were infected with either a <italic>hip</italic> or a low persister clinical isolate for 12 hrs and then treated with D-cycloserine (125 &#x003bc;g/ml) for 5 to 6 days and bacterial survival was determined by lysing the macrophages and plating for CFU (B). The values are an average of three biological replicates for each sample and the error bars represent standard deviation.</p></caption><graphic xlink:href="pone.0155127.g005"/></fig><p>TA modules have previously been associated with antibiotic tolerance. We therefore assessed the clinical isolate persister transcriptomes for each of the 79 TA modules identified to date in <italic>M</italic>. <italic>tuberculosis</italic> [<xref rid="pone.0155127.ref023" ref-type="bibr">23</xref>]. There were over 34 TA modules upregulated in both the <italic>hip</italic> and low persister transcriptomes and 15 that were uniquely upregulated in <italic>hip</italic> isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s026">S21 Table</xref>). Among the upregulated TA modules were the 10 identified in the previous <italic>M</italic>. <italic>tuberculosis</italic> H37Rv persister transcriptome [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>], including <italic>E</italic>. <italic>coli relE</italic> homologue (Rv2866) that is known for its involvement in <italic>M</italic>. <italic>tuberculosis</italic> drug tolerance [<xref rid="pone.0155127.ref024" ref-type="bibr">24</xref>].</p><p>Of the genes identified from the longitudinal study, phosphate-transport ATP-binding protein ABC transporter <italic>pstB</italic> (Rv0933) was downregulated in all strains and glutamine-transport transmembrane protein ABC transporter (Rv0072) was dramatically downregulated (&#x0003e;400-fold) in the <italic>hip</italic> isolates compared to the low persister isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s027">S22 Table</xref>). Of the clinical <italic>hip</italic> isolate mutations, the possible maturase gene (Rv0071) was also significantly downregulated in the <italic>hip</italic> compared to the low persister isolates (<xref ref-type="supplementary-material" rid="pone.0155127.s027">S22 Table</xref>). Of the <italic>in vitro hip</italic> mutant candidate genes identified by whole genome sequencing analysis, genes highly upregulated in both the <italic>hip</italic> and low persister isolates included <italic>gltA1</italic> (Rv1131), <italic>glpD1</italic> (Rv2249c), hypothetical protein (Rv2323c), and transcriptional regulator AsnC family (Rv2324) (<xref ref-type="supplementary-material" rid="pone.0155127.s027">S22 Table</xref>). Of the PDIM biosynthesis genes, <italic>fadD26</italic>, <italic>ppsA</italic> (Rv2931), and <italic>mas</italic> were significantly downregulated in both <italic>hip</italic> and low persister isolates while other PDIM genes showed variable expression (<xref ref-type="supplementary-material" rid="pone.0155127.s028">S23 Table</xref>). Of the 15 genes significantly differentially expressed in the <italic>hip</italic> mutants obtained <italic>in vitro</italic>, eight showed similar differential expression in the clinical <italic>hip</italic> compared to low persister isolates at day 0, prior to antibiotic treatment (<xref ref-type="supplementary-material" rid="pone.0155127.s029">S24 Table</xref>). Eight out of 15 genes highly expressed in H37Rv persister transcriptome [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>] were upregulated in both <italic>hip</italic> and low persister isolate transcriptomes (<xref ref-type="supplementary-material" rid="pone.0155127.s030">S25 Table</xref>).</p></sec></sec><sec id="sec011"><title>Clinical <italic>hip</italic> isolates in an <italic>ex vivo</italic> model of <italic>M</italic>. <italic>tuberculosis</italic> infection</title><p>With reduced killing of the <italic>hip</italic> clinical isolates by bactericidal antibiotics in the <italic>in vitro</italic> persister assays, we next sought to determine whether these isolates would exhibit a survival advantage in an <italic>ex vivo</italic> model of tuberculosis infection. Murine macrophages were infected with either a <italic>hip</italic> or a low persister clinical isolate. Once the infection was established, cells were treated with two separate antibiotics. To reduce variability between the <italic>in vitro</italic> and <italic>ex vivo</italic> assays, kanamycin and D-cycloserine were used. Even with moderate intracellular killing activity [<xref rid="pone.0155127.ref042" ref-type="bibr">42</xref>], these two antibiotics killed the low persister isolates to a greater extent than the <italic>hip</italic> isolates. Survival of the <italic>hip</italic> isolates was significantly higher (<italic>p</italic>-value &#x0003c; 0.05) than the low persister isolates at the later time points with D-cycloserine treatment (<xref ref-type="fig" rid="pone.0155127.g005">Fig 5B</xref>). Similar data were obtained using a two-fold higher concentration of antibiotic (<xref ref-type="supplementary-material" rid="pone.0155127.s005">S5 Fig</xref>). These results point to a link between the <italic>hip</italic> phenotype and increased <italic>ex vivo</italic> drug tolerance.</p></sec></sec><sec sec-type="conclusions" id="sec012"><title>Discussion</title><p>Persisters are thought to be responsible for the lengthy therapy of acute tuberculosis, and for the existence of the latent disease. In this study, we aimed to identify potential persister genes by studying high persister (<italic>hip</italic>) mutants (<xref ref-type="fig" rid="pone.0155127.g006">Fig 6</xref>). Repeated selection for cells surviving antibiotic treatment <italic>in vitro</italic> resulted in the formation of up to 1,000 times more persister cells by the <italic>hip</italic> mutants than by the parental wild type strain. Antibiotic therapy similarly exposes patients to periodic treatment with high levels of bactericidal drugs. Importantly, we also found <italic>hip</italic> mutants among human isolates, which links persisters to the clinical manifestation of disease.</p><fig id="pone.0155127.g006" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.g006</object-id><label>Fig 6</label><caption><title>Summary of the study of <italic>hip</italic> mutants in <italic>M</italic>. <italic>tuberculosis</italic>.</title><p>Schematic depicting the comparative analysis of <italic>hip</italic> mutants, generated <italic>in vitro</italic> and identified in clinical isolates, by whole genome sequencing and transcriptome analysis to identify candidate persister genes.</p></caption><graphic xlink:href="pone.0155127.g006"/></fig><p>Whole genome sequencing of <italic>hip</italic> mutants obtained <italic>in vitro</italic> identified several candidate persister genes. Multiple independent mutations were found within the PDIM biosynthetic operon. PDIM is an important cell wall lipid and virulence factor whose synthesis involves a large locus consisting of 13 genes. Repeated culture was reported to lead to a loss of PDIM; it is expensive to produce, and not required in vitro [<xref rid="pone.0155127.ref037" ref-type="bibr">37</xref>], [<xref rid="pone.0155127.ref043" ref-type="bibr">43</xref>], [<xref rid="pone.0155127.ref044" ref-type="bibr">44</xref>]. Indeed, PDIM-null mutants have a growth advantage [<xref rid="pone.0155127.ref037" ref-type="bibr">37</xref>]. We also find that PDIM mutants grow to a higher density. Since the frequency of persister formation is density dependent, the higher cell concentration of PDIM mutants could be responsible for their <italic>hip</italic> phenotype. Mutations in PDIM biosynthetic genes were also identified by whole genome sequencing of clinical isolates. While the <italic>ppsD</italic> (Rv2934) mutation in the <italic>hip</italic> clinical isolate 82 (S1132R) and <italic>mas</italic> (Rv2940c) mutation in <italic>hip</italic> isolate 102 (A195V) did not seem to be directly associated with any change in expression, transcriptome analysis showed significant downregulation of <italic>fadD26</italic>, <italic>ppsA</italic>, <italic>mas</italic>, <italic>fadD28</italic> (Rv2941), and transmembrane transport protein <italic>mmpL7</italic> (Rv2942) in various clinical isolates. The decreased expression of PDIM may allow <italic>M</italic>. <italic>tuberculosis</italic> to retain its virulence and at the same time increase the production of drug-tolerant persisters. The mechanism underlying the decreased expression of PDIM genes in <italic>hip</italic> mutants remains to be established.</p><p>Phospholipid biosynthesis has been associated with persister formation in <italic>E</italic>. <italic>coli</italic>. Mutations in <italic>plsB2</italic> (Rv2482c) and cdp-diacylglycerol pyrophospatase <italic>cdh</italic> (Rv2289), both involved in phospholipid biosynthesis were identified in <italic>hip</italic> mutants obtained <italic>in vitro</italic> and in clinical isolates. Mutations in <italic>plsB2</italic> were identified in <italic>hip</italic> mutant KL2826 (L221F), obtained <italic>in vitro</italic>, as well as in a <italic>hip</italic> clinical isolate 82 (R159H and D617H) and in a low persister clinical isolate 70 (R179Q and D328G). There was no obvious trend in differential expression of <italic>plsB2</italic> in the persister fraction from the clinical isolates, however, this gene was significantly downregulated in stationary phase compared to wild type (mc<sup>2</sup>6020) in several of the <italic>hip</italic> mutants obtained <italic>in vitro</italic> (KL2801, KL2849, KL1116, KL1130). Mutations in <italic>cdh</italic> were identified in <italic>hip</italic> mutant KL1120 (A122V) obtained <italic>in vitro</italic> as well as a <italic>hip</italic> clinical isolate 82 (K215I) and a low persister clinical isolate 76 (L233R). This gene was significantly downregulated in the persister fraction of the clinical isolates. Together this data further suggests that a decrease in phospholipid biosynthesis may be associated with persister formation in <italic>M</italic>. <italic>tuberculosis</italic>.</p><p>Besides phospholipid biosynthesis, alterations in other metabolic pathways are known to affect persister formation. For example, genes that inhibit lipid catabolism have been linked to drug tolerance [<xref rid="pone.0155127.ref028" ref-type="bibr">28</xref>]. Mutations in acyl-CoA dehydrogenase <italic>fadE30</italic> (Rv3560c), a gene involved in lipid degradation, were identified in a <italic>hip</italic> mutant KL2825 (R381W) obtained <italic>in vitro</italic> and in <italic>hip</italic> clinical isolate 82 (E34A) where it was found to be downregulated in the persister fraction. Changes in amino acid metabolism are also known to affect persistence [<xref rid="pone.0155127.ref045" ref-type="bibr">45</xref>]. Among the mutant genes differentiating the late isolate of our longitudinal study, a phosphate ABC transporter (Rv0933) and a glutamate ABC transporter (Rv0072) involved in amino acid metabolism, were identified. Importantly, the expression of Rv0072 was more than 400-fold lower in the <italic>hip</italic> isolates compared to the low persister isolates. Mutations in isoleucyl-tRNA synthetase <italic>ileS</italic> (Rv1536) were identified in <italic>hip</italic> mutant KL1134 (E728K) obtained <italic>in vitro</italic> and <italic>hip</italic> clinical isolate 82 (R39H). Also involved in amino acid biosynthesis and reported to be upregulated during Mg<sup>2+</sup> starvation [<xref rid="pone.0155127.ref046" ref-type="bibr">46</xref>], this gene was upregulated in the persister fraction of clinical isolate 82. We also observed a mutation in <italic>gltA1</italic> (Rv1131) and its upregulation in a <italic>hip</italic> mutant obtained <italic>in vitro</italic> (KL1117). While there were no mutations in <italic>gltA1</italic> in the clinical isolates, this gene was significantly upregulated in the persister fraction of all isolates. Upregulation of <italic>gltA1</italic> has been linked to a metabolic shift in carbon away from the TCA cycle, directly affecting antibiotic tolerance [<xref rid="pone.0155127.ref028" ref-type="bibr">28</xref>].</p><p>Pathways not previously associated with persister formation were also identified in our study. A single non-synonymous mutation in maturase-like protein (Rv0071) was unique to all four <italic>hip</italic> clinical isolates (A118V). This gene was significantly downregulated in the <italic>hip</italic> clinical isolates. Little is known about RNA maturation enzymes in bacteria. They function like group II introns and may play a role in RNA editing [<xref rid="pone.0155127.ref047" ref-type="bibr">47</xref>]. In addition, mutations in the probable transcriptional regulator of the AsnC family (Rv2324) were identified in several <italic>hip</italic> mutants obtained <italic>in vitro</italic> (KL1090, KL1105, KL1116, KL1117). AsnC regulatory proteins are known as the &#x02018;feast or famine&#x02019; proteins in bacteria and are involved in direct regulation of multiple genes in response to environmental signals [<xref rid="pone.0155127.ref040" ref-type="bibr">40</xref>]. While no mutations were found in the clinical isolates, this transcriptional regulator was significantly upregulated over 16-fold in the persister fraction of three <italic>hip</italic> clinical isolates (82, 98, 102). Another candidate identified was transcriptional regulator Rv1395, known to induce the expression of cytochrome P450 gene Rv1394 [<xref rid="pone.0155127.ref048" ref-type="bibr">48</xref>]. Mutations in Rv1395 were identified in <italic>hip</italic> mutant KL2801 (P208L) obtained <italic>in vitro</italic> and in <italic>hip</italic> clinical isolates 65 (I105M) and 82 (R220C). This gene was significantly upregulated in the persister fraction of all eight clinical isolates and as such it is an interesting candidate for further analysis.</p><p>Transcriptome analysis revealed an upregulation in TA module expression in the persister fraction of <italic>M</italic>. <italic>tuberculosis</italic> clinical isolates. Various TA modules induce drug tolerance in <italic>M</italic>. <italic>smegmatis</italic>, <italic>M</italic>. <italic>tuberculosis</italic>, and <italic>E</italic>. <italic>coli</italic> [<xref rid="pone.0155127.ref007" ref-type="bibr">7</xref>], [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>], [<xref rid="pone.0155127.ref023" ref-type="bibr">23</xref>]. One of the most upregulated TA modules identified in our study was <italic>HigBA1</italic> (Rv1955-Rv1957). This is a tripartite module comprised of toxin-antitoxin-chaperone (TAC) where activation of the toxin likely requires unavailability of the chaperone and/or degradation of the antitoxin [<xref rid="pone.0155127.ref023" ref-type="bibr">23</xref>]. Interestingly, the antitoxin HigA1 (Rv1956) of this TAC is a putative regulator of the fatty acid metabolism gene cluster Rv2930-Rv2939, comprising PDIM biosynthetic genes including <italic>fadD26</italic> [<xref rid="pone.0155127.ref049" ref-type="bibr">49</xref>]. It is also capable or interacting with the stress response gene cluster Rv3249-Rv3252, including <italic>rubA</italic> and <italic>rubB</italic>, which were upregulated in the <italic>hip</italic> mutants obtained <italic>in vitro</italic>. While only one mutation was identified in this TAC module in our study (clinical isolate 73; Rv1957, D83N), the notable transcriptional profile and association with other persister gene candidates provides some evidence for a putative role in the <italic>hip</italic> phenotype. Moreover, we found that, just as with H37Rv [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>], <italic>clpC2</italic> (Rv2667) was upregulated in the persister fraction of clinical isolates. Since proteases typically degrade antitoxins leading to toxin-mediated drug tolerance, this further supports a role for TA modules in <italic>M</italic>. <italic>tuberculosis</italic> persister formation.</p><p>The identification of <italic>hip</italic> mutants in longitudinal isolates of <italic>C</italic>. <italic>albicans</italic> [<xref rid="pone.0155127.ref032" ref-type="bibr">32</xref>] and <italic>P</italic>. <italic>aeruginosa</italic> [<xref rid="pone.0155127.ref033" ref-type="bibr">33</xref>] suggests that <italic>hip</italic> mutants may be a general feature of recalcitrant infectious diseases. Our identification of <italic>hip</italic> clinical isolates of <italic>M</italic>. <italic>tuberculosis</italic> supports this possibility. Interestingly, infection with the <italic>hip</italic> clinical isolate 67 resulted in relapse whereas infection with none of the low persister isolates did (<xref ref-type="supplementary-material" rid="pone.0155127.s014">S9 Table</xref>). Note that <italic>hip</italic> isolate 102 was isolated from a patient with a history of four repeated episodes of tuberculosis. The <italic>hip</italic> clinical isolates showed increased drug tolerance both <italic>in vitro</italic> and in an <italic>ex vivo</italic> model of tuberculosis. These findings are in agreement with a previous report of delayed killing <italic>in vitro</italic> of <italic>M</italic>. <italic>tuberculosis</italic> isolates from patients with relapse [<xref rid="pone.0155127.ref050" ref-type="bibr">50</xref>].</p><p>The results of this study reveal an overlap in genes and pathways we identified by transcriptome analysis of persisters and genomic analysis of <italic>hip</italic> mutants with those reported to be associated with persister formation, such as TA modules and carbon and amino acid metabolism. Our study also points to novel genes that may be unique to <italic>M</italic>. <italic>tuberculosis</italic> persisters, such as lipid biosynthesis and feast or famine regulation. Knowledge of <italic>M</italic>. <italic>tuberculosis</italic> persister cells will facilitate development of effective therapies for their eradication.</p></sec><sec sec-type="materials|methods" id="sec013"><title>Materials and Methods</title><sec id="sec014"><title>Strains, media and culture conditions</title><p>Bacterial strains used in this study are shown in <xref ref-type="table" rid="pone.0155127.t002">Table 2</xref>. <italic>M</italic>. <italic>tuberculosis</italic> H37Rv double auxotroph strain mc<sup>2</sup>6020 [<xref rid="pone.0155127.ref035" ref-type="bibr">35</xref>] was used as the parental strain of the <italic>in vitro hip</italic> mutants. Clinical isolates included in this study were obtained from new tuberculosis cases and retreatment cases of subjects enrolled in a prospective longitudinal cohort study (ClinicalTrials.gov identifier, NCT00341601) at the National Masan Hospital (NMH) in the Republic of Korea. The institutional review boards of National Institute of Allergy and Infectious Diseases (NIAID) and NMH approved the study and all subjects gave written informed consent. H37Rv (American Type Culture Collection [ATCC] No. 27294) was used as the wild type strain in the clinical isolate experiments. PDIM mutant strains mc<sup>2</sup>3105 [<xref rid="pone.0155127.ref036" ref-type="bibr">36</xref>] and <italic>drrA</italic>::Tn [<xref rid="pone.0155127.ref038" ref-type="bibr">38</xref>] were kindly provided. Strains were grown in Middlebrook 7H9 Broth or on 7H10 Agar (Difco) medium supplemented with 10% oleic acid-albumin-dextrose-catalase (OADC) (Difco), 0.2&#x02013;0.5% glycerol, either 0.05% Tween-80 (clinical isolate broth experiments) or 0.05% tyloxapol (<italic>in vitro hip</italic> mutant broth experiments), and required supplements for the double auxotroph mc<sup>2</sup>6020 [<xref rid="pone.0155127.ref035" ref-type="bibr">35</xref>] including 0.2% casamino acids (Amresco), pantothenic acid (24 &#x003bc;g/ml), and lysine (80 &#x003bc;g/ml). Freezer stocks were diluted 1:100 into 7H9 broth medium and grown in a shaking incubator at 37&#x000b0;C at 100 rpm. Minimal media was prepared as previously described [<xref rid="pone.0155127.ref051" ref-type="bibr">51</xref>] with 0.5% glycerol (vol/vol), 0.1% butyrate (wt/vol), or 0.1% propionate (wt/vol), 0.05% tyloxapol (vol/vol), pantothenic acid (24 &#x003bc;g/ml), and lysine (80 &#x003bc;g/ml). The clinical isolates were grown first on Lowenstein-Jensen slants and then transferred to 7H9 media prior to freezing stocks. To limit the introduction of genetic mutations due to <italic>in vitro</italic> growth conditions, the number of passages of strains from the original stock was limited to a maximum of five in accordance with ATCC recommendations. All chemicals were obtained from Sigma-Aldrich unless otherwise indicated. The antibiotics and their concentrations used in this study were streptomycin (10 &#x003bc;g/ml), rifampicin (1 &#x003bc;g/ml), kanamycin (50 &#x003bc;g/ml), ofloxacin (10 &#x003bc;g/ml), hygromycin (50 &#x003bc;g/ml), D-cycloserine (125 &#x003bc;g/ml), and moxifloxacin (20 &#x003bc;g/ml) (Waterstone Technology). Antibiotic stocks were prepared as recommended [<xref rid="pone.0155127.ref052" ref-type="bibr">52</xref>] and subsequent dilutions were made in 7H9 broth medium.</p><table-wrap id="pone.0155127.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0155127.t002</object-id><label>Table 2</label><caption><title>Bacterial strains used in this study.</title></caption><alternatives><graphic id="pone.0155127.t002g" xlink:href="pone.0155127.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Strain Name</th><th align="left" rowspan="1" colspan="1">SRA Accession Number</th><th align="left" rowspan="1" colspan="1">Description</th><th align="left" rowspan="1" colspan="1">Parent Strain Name</th><th align="left" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">H37Rv &#x00394;<italic>lysA</italic> &#x00394;<italic>panCD</italic></td><td align="left" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">[<xref rid="pone.0155127.ref035" ref-type="bibr">35</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2801</td><td align="left" rowspan="1" colspan="1">SRX014112</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2801</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2802</td><td align="left" rowspan="1" colspan="1">SRX016225</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2802</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2803</td><td align="left" rowspan="1" colspan="1">SRX014110</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2803</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2825</td><td align="left" rowspan="1" colspan="1">SRX016226</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2825</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2826</td><td align="left" rowspan="1" colspan="1">SRX016227</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2826</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2827</td><td align="left" rowspan="1" colspan="1">SRX016228</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2827</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2849</td><td align="left" rowspan="1" colspan="1">SRX014107</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2849</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2850</td><td align="left" rowspan="1" colspan="1">SRX014911</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2850</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL2851</td><td align="left" rowspan="1" colspan="1">SRX014909</td><td align="left" rowspan="1" colspan="1">Hip mutant KL2851</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1090</td><td align="left" rowspan="1" colspan="1">SRX005187</td><td align="left" rowspan="1" colspan="1">Hip mutant HTS1090</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1105</td><td align="left" rowspan="1" colspan="1">SRX000677</td><td align="left" rowspan="1" colspan="1">Hip mutant HTS1105</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1116</td><td align="left" rowspan="1" colspan="1">SRX081440</td><td align="left" rowspan="1" colspan="1">Hip mutant HT1116</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1117</td><td align="left" rowspan="1" colspan="1">SRX081849</td><td align="left" rowspan="1" colspan="1">Hip mutant HT1117</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1120</td><td align="left" rowspan="1" colspan="1">SRX081404</td><td align="left" rowspan="1" colspan="1">Hip mutant HT1120</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1130</td><td align="left" rowspan="1" colspan="1">SRX081415</td><td align="left" rowspan="1" colspan="1">Hip mutant HT1130</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1134</td><td align="left" rowspan="1" colspan="1">SRX081412</td><td align="left" rowspan="1" colspan="1">Hip mutant HT1134</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1137</td><td align="left" rowspan="1" colspan="1">SRX081421</td><td align="left" rowspan="1" colspan="1">Hip mutant HT1137</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">KL1170</td><td align="left" rowspan="1" colspan="1">SRX081442</td><td align="left" rowspan="1" colspan="1">Hip mutant HT1170</td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">p-<italic>glpD1</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020 carrying pTET<italic>glpD1</italic>, Kan<sup>R</sup></td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">p-<italic>glpD1</italic>-flag</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020 carrying pTET<italic>glpD1</italic>-flag, Kan<sup>R</sup></td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">p-<italic>plsB2</italic></td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020 carrying pTET<italic>plsB2</italic>, Kan<sup>R</sup></td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1">p-<italic>plsB2</italic>-flag</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020 carrying pTET<italic>plsB2</italic>-flag, Kan<sup>R</sup></td><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>6020</td><td align="left" rowspan="1" colspan="1">This study</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>fadD26</italic>::Tn (Erdman)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">mc<sup>2</sup>3105, Erdman <italic>fadD26</italic>::Tn5370, Hyg<sup>R</sup></td><td align="left" rowspan="1" colspan="1">Erdman</td><td align="left" rowspan="1" colspan="1">[<xref rid="pone.0155127.ref036" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Wild type (Erdman)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Wild type</td><td align="left" rowspan="1" colspan="1">Erdman</td><td align="left" rowspan="1" colspan="1">[<xref rid="pone.0155127.ref036" ref-type="bibr">36</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Wild type (H37Rv)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">H37Rv carrying JEB403, Kan<sup>R</sup></td><td align="left" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">[<xref rid="pone.0155127.ref038" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>drrA</italic>::Tn (H37Rv)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">H37Rv <italic>drrA</italic>::Tn.1 carrying JEB403, Hyg<sup>R</sup>, Kan<sup>R</sup></td><td align="left" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">[<xref rid="pone.0155127.ref038" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>drrA</italic>::Tn + complement (H37Rv)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">H37Rv <italic>drrA</italic>::Tn.1 carrying JEB<italic>drrA</italic>, Hyg<sup>R</sup>, Kan<sup>R</sup></td><td align="left" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">[<xref rid="pone.0155127.ref038" ref-type="bibr">38</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Wild type (ATCC 27294)</td><td align="left" rowspan="1" colspan="1">H37Rv</td><td align="left" rowspan="1" colspan="1">ATCC</td></tr><tr><td align="left" rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">61</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">62</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">63</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">67</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">68</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">69</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">70</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">71</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">72</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">73</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">76</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">79</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">82</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">83</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">94</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">96</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">98</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">101</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">102</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">104</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">107</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">115</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">118</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">121</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">124</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">125</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">126</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">127</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">140</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">141</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">145</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">149</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">150</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">151</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">170</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr><tr><td align="left" rowspan="1" colspan="1">186</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Clinical isolate</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">ClinicalTrials.gov identifier, NCT00341601</td></tr></tbody></table></alternatives></table-wrap></sec><sec id="sec015"><title>Mutant strains and plasmid construction</title><p>Chemical mutagenesis was performed as previously described [<xref rid="pone.0155127.ref053" ref-type="bibr">53</xref>] with modifications. Strain mc<sup>2</sup>6020 was grown to exponential phase with an optical density at 600 nm (OD<sub>600</sub>) of 0.8 and washed two times with equal volumes of minimal A buffer (K<sub>2</sub>HPO<sub>4</sub> 10.5 mg/ml, KH<sub>2</sub>PO<sub>4</sub> 4.5 mg/ml, [NH<sub>4</sub>]<sub>2</sub>SO<sub>4</sub> 1 mg/ml, [C<sub>6</sub>H<sub>5</sub>Na<sub>3</sub>O<sub>7</sub>]<sub>2</sub>H<sub>2</sub>O 0.5 mg/ml). Bacterial cells were resuspended in an equal volume of minimal A buffer. The cultures were split into 20 ml aliquots, 300 &#x003bc;l of ethyl methanesulfonate was added, and cultures were incubated on a shaker (100 rpm) at 37&#x000b0;C for 60 min. Mutagenized cells were washed two times with equal volumes of minimal A buffer and resuspended in 220 ml of 7H9 medium in 1,300 ml roller bottles (Corning). The roller bottles were incubated on a roller platform (6 rpm) at 37&#x000b0;C for one week until the culture reached stationary phase. Cultures were then diluted 1:100 into 40 ml of 7H9 medium, grown to exponential phase (OD<sub>600</sub> 0.8) and then treated with a combination of streptomycin (10 &#x003bc;g/ml) and rifampicin (1 &#x003bc;g/ml) for one week. Cells were washed once with an equal volume of phosphate buffered saline (PBS) and resuspended in 40 ml of 7H9 medium. Before and after the antibiotic challenges, samples were taken for bacterial cell enumeration. The enrichment procedure was repeated. The washed cells were grown again to stationary phase, diluted 1:100, grown to exponential phase, and treated for one week using the same antibiotic combination. After the fourth round of enrichment individual strains were separated from the mutagenized populations by isolating individual colonies for further characterization.</p><p>Overexpression plasmids were constructed by cloning candidate genes using Phusion<sup>&#x000ae;</sup> High-Fidelity DNA Polymerase (New England Biolabs) with the primers listed in <xref ref-type="supplementary-material" rid="pone.0155127.s006">S1 Table</xref>. Cloned products were ligated into the Gateway<sup>&#x000ae;</sup> Cloning system (Invitrogen) and then transferred to an expression vector (pTET) containing a tetracycline inducible mycobacterial promoter [<xref rid="pone.0155127.ref054" ref-type="bibr">54</xref>]. Purified plasmids were transformed into <italic>M</italic>. <italic>tuberculosis</italic> mc<sup>2</sup>6020 and selected for using kanamycin (50 &#x003bc;g/ml). Overexpression strains were induced 72 hrs prior to antibiotic challenge by addition of anhydrous tetracycline (aTc) (100 ng/ml) to the media.</p></sec><sec id="sec016"><title>Persister assay</title><p>To determine the level of persister formation in various strains and under various conditions, antibiotic treatments were performed in biological triplicate as previously described [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>]. For stationary phase treatments, the initial two-week-old cultures were diluted 1:100 and grown for an additional two weeks prior to antibiotic treatment. For persister assays with the clinical isolates, freezer stocks were diluted 1:10 into broth media and grown for three weeks to stationary phase. Clinical isolate cultures were then diluted 1:100 into fresh broth media and grown for four to five days for exponential phase challenge or for three weeks for stationary phase challenge. Samples were plated at selected time points and bacterial survival was monitored by enumeration of colony forming units (CFU). The Student&#x02019;s T-test was used to determine significant differences and Spearman&#x02019;s Rank-order test was used to assess correlation.</p></sec><sec id="sec017"><title>Growth rate determination</title><p><italic>Hip</italic> mutant and wild type (mc<sup>2</sup>6020) strains were grown in triplicate in standard 7H9 liquid media and samples were taken at the indicated time points for cell enumeration by plating for CFU from which the generation time was calculated [<xref rid="pone.0155127.ref055" ref-type="bibr">55</xref>]. The data represent an average of three biological replicates plus or minus the standard deviation.</p></sec><sec id="sec018"><title>Drug resistance assays</title><p>The drug sensitivity testing (DST) of clinical isolates was performed on solid media with absolute concentrations of first- and second-line anti-tuberculosis drugs. The anti-tuberculosis drugs that were tested included isoniazid (INH/H), rifampicin (RIF/R), streptomycin (SM/S), ethambutol (EMB/E), kanamycin (KM/K), capreomycin (CPM), prothionamide (PTH/T), cycloserine (CS/C), para-aminosalicylic acid (PAS/P), ofloxacin (OFX/O), moxifloxacin (MOX), amikacin (AMK), levofloxacin (LEV/Lf), rifabutin (RBU), and pyrazinamide (PZA/Z). The testing was carried out at the NMTH and the NIH according to standard guidelines for DST.</p><p>The MIC testing was liquid-based using the micro-plate based Alamar Blue assay as described [<xref rid="pone.0155127.ref056" ref-type="bibr">56</xref>] with minor modifications. Cultures was grown to early exponential phase (OD<sub>600</sub> 0.3) and diluted to 1:100 for the assay. Antibiotics were serially diluted in 96-well plates and equal volumes of diluted bacterial cultures were added. The plates were sealed with Breathe-Easy<sup>&#x000ae;</sup> (3M Company) and incubated at 37&#x000b0;C. After four days, 20 &#x003bc;l of Alamar Blue (Serotec) was added to each well and the plates were resealed and incubated for 24 to 48 hrs. The colors of all wells were recorded after visual inspection and absorbance measurement using the Synergy HT microplate reader (BioTek) with excitation and emission wavelengths of 530 nm and 590 nm, respectively.</p></sec><sec id="sec019"><title>Total lipid analysis by thin layer chromatography</title><p>Total lipids were extracted by centrifugation of bacterial cells (4,000 rpm, 15 min) at room temperature. Pellets were resuspended in 5 ml of 2:1 CHCl<sub>3</sub>:MeOH and transferred to a clean glass centrifuge tube with a Teflon-lined cap. To the glass tube, 25 ml of CHCl<sub>3</sub>:MeOH (2:1) was added and lipids were extracted for at least 1 hr on an orbital rocker. Tubes were centrifuged (2,000 rpm, 15 min) at room temperature and supernatants were transferred to clean glass tubes. Pellets were resuspended in 30 mL of CHCl<sub>3</sub>:MeOH (1:1) and lipids extracted as above. Pellets were resuspended for a final time in 30 mL of CHCl<sub>3</sub>:MeOH (1:2). The organic phases were combined and evaporated using a rotovap. Extracted lipids were dissolved in CHCl<sub>3</sub>:MeOH (1:1) and 150 &#x003bc;g of each sample were spotted onto a 20 x 20 cm silica glass plate (84101, Scientific Adsorbents). Petroleum either:diethyl ether (90:10) was used as the solvent and the revelation solution consisted of 8% H<sub>3</sub>PO<sub>4</sub> (vol/vol) and 3% Cu Acetate (wt/vol) in water. Plates were sprayed and heated in an oven to 160&#x000b0;C.</p></sec><sec id="sec020"><title>Genomic DNA extraction and whole genome sequencing</title><p>Genomic DNA was isolated as previously described [<xref rid="pone.0155127.ref057" ref-type="bibr">57</xref>]. The concentration of genomic DNA was measured using a NanoDrop spectrophotometer (Thermo Scientific) and stored at -20&#x000b0;C. The Illumina paired-end reads design was used for whole genome sequencing of genomic DNA from the <italic>hip</italic> mutant and wild type (mc<sup>2</sup>6020) strains. All sequencing was performed at the Broad Institute (Cambridge, MA). Illumina fragment libraries were generated as previously described [<xref rid="pone.0155127.ref058" ref-type="bibr">58</xref>] with the following modifications. For each sample, 100 ng of genomic DNA was sheared to 200 bp in size using a Covaris LE220 instrument (Covaris, MA) with the following parameters: temperature: 7&#x02013;9&#x000b0;C; duty cycle: 20%; intensity: 5; cycles per burst: 200; time: 90 sec; shearing tubes: Crimp Cap microTUBES with AFA fibers (Covaris, MA). DNA fragments were end repaired, 3&#x02032; adenylated, ligated with indexed Illumina sequencing adapter, and PCR enriched, as previously described [<xref rid="pone.0155127.ref059" ref-type="bibr">59</xref>]. The resulting Illumina fragment sequencing libraries were normalized and were size selected to contain inserts of 180 bp &#x000b1; 3% in length using a Pippen Prep system (Sage Science, MA) following the manufacturer&#x02019;s recommendations. Sequencing coverage is presented (<xref ref-type="supplementary-material" rid="pone.0155127.s007">S2 Table</xref>) and the data is available at the National Center for Biotechnology Information (NCBI) sequence read archive (SRA) under BioProject PRJNA38649. Sequenced strains were aligned to the fully assembled H37Rv library. The library name was Solexa-16183, source was genomic, selection was random, and layout was paired with a 5&#x02019;3&#x02019;-3&#x02019;5&#x02019; orientation, a nominal length of 166, and a nominal standard deviation of 34.33. Coding single nucleotide polimorphisms (SNPs) as well as insertions and deletions that were identified between the <italic>hip</italic> mutants and the H37Rv reference assembly and that did not occur in the parental wild type strain (mc<sup>2</sup>6020) were classified as mutations. For analysis of the clinical isolates, we considered any coding SNP identified between each isolate and the H37Rv reference strain as a mutation.</p></sec><sec id="sec021"><title>Transcriptome analysis</title><p>In collaboration with the Broad Institute (Cambridge, MA), Affymetrix microarray technology was used for conducting the transcriptome analysis of the <italic>in vitro</italic> generated <italic>hip</italic> mutant strains. Total RNA was extracted as previously described [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>] from stationary phase cultures that were grown for 14 days from a 1:100 inoculum. Quality control of microarray data in our study was measured with RNA degradation and box plots. RNA degradation starts from the 5&#x02019; end to 3&#x02019; end so 5&#x02019; end probes show lower intensities than the 3&#x02019; end probes. RNA degradation plots measure this trend and a high slope indicates degradation. In this study RNA degradation was minimal. A boxplot is a tool to summarize intensity distributions and indicate if there are any sample outliers. Differences in amplification or labeling tend to cause these outliers. Our study did not show any outliers. Statistical analysis of the data was performed using the Bioconductor program and oneChannelGUI package [<xref rid="pone.0155127.ref060" ref-type="bibr">60</xref>] available through the R Project for Statistical Computing (<ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">www.r-project.org</ext-link>). Data is presented as log2 fold change. The microarray data have been deposited in NCBI&#x02019;s Gene Expression Omnibus (GEO) [<xref rid="pone.0155127.ref061" ref-type="bibr">61</xref>] and are accessible through GEO Series accession number GSE55647.</p><p>For transcriptome analysis of the clinical isolates, cultures were grown from a 1:100 inoculum to mid-exponential phase (OD<sub>600</sub> 0.5) and then treated with D-cycloserine (125 &#x003bc;g/ml). Culture samples were collected at Day 0 (2 ml) and Day 7 (40 ml) of treatment for RNA isolation as previously described [<xref rid="pone.0155127.ref021" ref-type="bibr">21</xref>]. Strand-specific RNAseq libraries were created by the Broad Technology Labs specialized service facility as described [<xref rid="pone.0155127.ref062" ref-type="bibr">62</xref>]. Briefly, 48 RNA samples were fragmented, and RNA 3&#x02019; ends were tagged with a DNA oligonucleotide containing a sample barcode and a partial 5&#x02019; Illumina adapter. Resulting barcoded RNAs were then pooled and subjected to rRNA depletion with RiboZero (Epicentre), cDNA synthesis and ligation to a second oligonucleotide containing a partial Illumina 3&#x02019; adapter. A second barcode specific to this pool was then added by amplification with full-length barcoded Illumina adapter primers, yielding a single strand-specific sequence-ready pooled RNA-seq library. The pool of 48 Illumina RNAseq libraries was quantified using qPCR (KAPA Biosystems) and sequenced with 76 base paired-end reads across 4 lanes using an Illumina HiSeq 2000 sequencer (Illumina) running v3 SBS chemistry. Sequence data were processed and demultiplexed using the Picard analysis pipeline (<ext-link ext-link-type="uri" xlink:href="http://picard.sourceforge.net">http://picard.sourceforge.net</ext-link>). Reads were aligned to the genome of <italic>M</italic>. <italic>tuberculosis</italic> H37Rv (RefSeq NC_000962) using BWA [<xref rid="pone.0155127.ref063" ref-type="bibr">63</xref>] version 5.9. Gene annotations were obtained from RefSeq and Rfam [<xref rid="pone.0155127.ref064" ref-type="bibr">64</xref>]. The overall fragment coverage of genomic regions corresponding to features such as ORFs and rRNAs was conducted as described [<xref rid="pone.0155127.ref065" ref-type="bibr">65</xref>]. RNAseq coverage metrics are presented (<xref ref-type="supplementary-material" rid="pone.0155127.s008">S3 Table</xref>). Differential expression analysis was conducted using DESeq [<xref rid="pone.0155127.ref066" ref-type="bibr">66</xref>]. Data is presented as log2 fold change. The RNAseq data are accessible through GEO Series accession number GSE62025.</p></sec><sec id="sec022"><title>Immunoblot analysis</title><p>Flag-tagged proteins were visualized by immunoblot analysis. Proteins were extracted from bacterial cells by centrifugation (11,000 rpm, 15 min), followed by resuspension of the pellet in 250 &#x003bc;l of Bacterial Protein Extraction Regent (Thermo Scientific Pierce). Samples were placed in a bead beater tube with Lysing matrix B (MP Biochemicals), and disrupted by bead beating using FastPrep-24 (MP Biochemicals) for 45 sec at the power setting of 6. Proteins were separated on NuPAGE Novex 4&#x02013;12% Bis-Tris Gels (Invitrogen) and transferred to nitrocellulose membranes. Monoclonal ANTI-FLAG<sup>&#x000ae;</sup> M1 antibody produced in mouse (F30401; Sigma) was used at a dilution of 1:1,000. Membranes treated with the WesternBreeze<sup>&#x000ae;</sup> Chemiluminescent Kit, anti-mouse (Invitrogen) according to the manufacturer&#x02019;s instructions. Blots were developed with an X-ray developing system.</p></sec><sec id="sec023"><title>Macrophage infections</title><p>The murine leukemic monocyte macrophage cell line RAW264.7 (ATCC) was used for all macrophage infections. Macrophages were propagated in Dulbecco&#x02019;s Modification of Eagle&#x02019;s Media with high glucose (Invitrogen) with 10% Fetal Bovine Serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 10 mM HEPES, and 1% penicillin/streptomycin (optional) at 37&#x000b0;C with 5% CO<sub>2</sub>. Cells were grown to confluence and then seeded in 6-well plates at a concentration of 1 x 10<sup>6</sup> cells per well and allowed to adhere to the surface of the plate overnight at 37&#x000b0;C with 5% CO<sub>2</sub>. Bacteria were grown to early exponential phase (OD<sub>600</sub> 0.3) in 40 ml of 7H9 broth and collected by centrifugation (4,000 rpm, 10 min). Cells were resuspended in 5 ml of macrophage media (without penicillin/streptomycin), sonicated three times (5 sec) at amplitude 4 on the Misonix Ultrasonic Liquid Processor S-4000 (Qsonica), and vortexed three times (5 sec). The volume was brought to 40 ml with macrophage media (without penicillin/streptomycin) and the remaining clumps were allowed to settle for 15 min after which the top 35 ml was transferred to a new tube. The OD<sub>600</sub> was measured and adjusted to 0.08 (~1 x 10<sup>7</sup> CFU/ml). Bacteria were deposited in the 6-well plates containing macrophages at a multiplicity of infection of 10: 1 (bacteria: macrophages) for 12 hrs after which the extracellular bacteria were washed away five times and fresh media with or without antibiotics was added. At selected time points macrophages were lysed with 0.5% Triton-100 in PBS, serially diluted in PBS, and plated on 7H10 media for bacterial cell enumeration.</p></sec></sec><sec sec-type="supplementary-material" id="sec024"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0155127.s001"><label>S1 Fig</label><caption><title>Thin layer chromatography of total lipid extracts.</title><p>Total lipid extract (150 &#x003bc;g) from each strain was spotted on the plate along with a DIM-A standard and run in petroleum ether / diethyl ether (90/10) solvent. Spots were visualized by treating the plate with H<sub>3</sub>PO<sub>4</sub> (8% v/v), Cu Acetate (3% v/v) and heat (140&#x02013;160&#x000b0;C). DIM-A is present in the wild type strain (mc<sup>2</sup>6020) and <italic>hip</italic> mutant KL1116 but absent in all of the other <italic>hip</italic> mutant strains.</p><p>(TIF)</p></caption><media xlink:href="pone.0155127.s001.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s002"><label>S2 Fig</label><caption><title>Persister assay of <italic>drrA</italic>::Tn PDIM mutant.</title><p>The <italic>drrA</italic>::Tn mutant and complemented strain along with wild type (H37Rv) were grown to either exponential or stationary phase and treated with streptomycin (10 &#x003bc;g/ml) and rifampicin (1 &#x003bc;g/ml) for 14 days. Survival was monitored by CFU counts. The values are an average of three biological replicates and error bars represent standard deviation.</p><p>(TIF)</p></caption><media xlink:href="pone.0155127.s002.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s003"><label>S3 Fig</label><caption><title>Overexpression of candidate persister genes <italic>glpD1</italic> and <italic>plsB2</italic>.</title><p>Overexpression strains were induced with aTc (100 ng/&#x003bc;l) 72 hrs prior to antibiotic treatment. Induced overexpression of <italic>glpD1</italic> (A) and <italic>plsB2</italic> (B) resulted in no change in level of persister formation in either exponential or stationary phase. Immunoblot analysis confirms overexpression (right). The values are an average of three biological replicates and error bars represent standard deviation.</p><p>(TIF)</p></caption><media xlink:href="pone.0155127.s003.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s004"><label>S4 Fig</label><caption><title>Characterization of persister level in clinical isolates.</title><p>Individual drug sensitive clinical isolates were treated in stationary phase with moxifloxacin (20 &#x003bc;g/ml) (A) or rifampicin (10 &#x003bc;g/ml) (B) for 14 days and bacterial survival was determined plating for CFU. The values are an average of three biological replicates and error bars represent standard deviation.</p><p>(TIF)</p></caption><media xlink:href="pone.0155127.s004.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s005"><label>S5 Fig</label><caption><title>Antibiotic tolerance of <italic>hip</italic> and low persister clinical isolates during macrophage infection.</title><p>Murine macrophages were infected with either a <italic>hip</italic> or a low persister clinical isolate for 12 hrs and then treated with either kanamycin (250 &#x003bc;g/ml) or D-cycloserine (250 &#x003bc;g/ml) for up to 6 days. Bacterial survival was determined by plating for CFU after lysing the macrophages. The values are an average of three biological replicates for each sample and the error bars represent standard deviation.</p><p>(TIF)</p></caption><media xlink:href="pone.0155127.s005.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s006"><label>S1 Table</label><caption><title>Oligonucleotides used in this study.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s006.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s007"><label>S2 Table</label><caption><title>Whole genome sequencing coverage metrics.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s007.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s008"><label>S3 Table</label><caption><title>RNAseq coverage metrics.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s008.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s009"><label>S4 Table</label><caption><title>Minimum inhibitory concentration of antibiotics for wild type (mc<sup>2</sup>6020) and <italic>in vitro hip</italic> mutant strains.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s009.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s010"><label>S5 Table</label><caption><title>Generation time (hrs) of wild type (mc<sup>2</sup>6020) and <italic>in vitro hip</italic> mutant strains under normal growth conditions.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s010.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s011"><label>S6 Table</label><caption><title>Stationary phase gene expression of <italic>hip</italic> mutant versus wild type (mc<sup>2</sup>6020) of genes identified by whole genome sequencing of the 12 independent <italic>in vitro hip</italic> mutants.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s011.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s012"><label>S7 Table</label><caption><title>Differential expression of top upregulated genes of three independent <italic>in vitro</italic> hip mutants (KL2801, KL2925, KL2849) versus wild type (mc<sup>2</sup>6020) in stationary phase.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s012.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s013"><label>S8 Table</label><caption><title>Differential expression of 12 independent <italic>in vitro hip</italic> mutants versus wild type (mc<sup>2</sup>6020) in stationary phase.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s013.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s014"><label>S9 Table</label><caption><title>Clinical isolate treatment history and drug resistance profile.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s014.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s015"><label>S10 Table</label><caption><title>Minimum inhibitory concentration of kanamycin for longitudinal clinical isolates and H37Rv.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s015.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s016"><label>S11 Table</label><caption><title>Minimum inhibitory concentration of antibiotics for clinical isolates and H37Rv.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s016.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s017"><label>S12 Table</label><caption><title>Total number of non-synonymous SNPs in clinical isolates compared to reference strain H37Rv.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s017.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s018"><label>S13 Table</label><caption><title>Non-synonymous SNPs differences between longitudinal isolates of Case 3 (94 and 96) compared to Case 1 (127 and 130).</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s018.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s019"><label>S14 Table</label><caption><title>Non-synonymous mutations unique to <italic>hip</italic> or low persister clinical isolates.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s019.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s020"><label>S15 Table</label><caption><title>Non-synonymous SNPs in the clinical isolates that occur in the same genes as mutations in the <italic>in vitro hip</italic> mutants.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s020.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s021"><label>S16 Table</label><caption><title>Genes upregulated (&#x0003e;4-fold) in all four <italic>hip</italic> clinical isolates.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s021.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s022"><label>S17 Table</label><caption><title>Genes upregulated (&#x0003e;4-fold) in all four low persister clinical isolates.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s022.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s023"><label>S18 Table</label><caption><title>Genes downregulated (&#x0003e;4-fold) in all four <italic>hip</italic> clinical isolates.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s023.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s024"><label>S19 Table</label><caption><title>Genes downregulated (&#x0003e;4-fold) in all four low persister clinical isolates.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s024.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s025"><label>S20 Table</label><caption><title>Genes upregulated (&#x0003e;4-fold) in <italic>hip</italic> versus low persister clinical isolates.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s025.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s026"><label>S21 Table</label><caption><title>Clinical isolate transcriptome analysis of <italic>M</italic>. <italic>tuberculosis</italic> TA module genes.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s026.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s027"><label>S22 Table</label><caption><title>Clinical isolate transcriptome analysis of candidate genes identified through whole genome sequencing.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s027.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s028"><label>S23 Table</label><caption><title>Clinical isolate transcriptome analysis of PDIM biosynthetic operon genes.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s028.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s029"><label>S24 Table</label><caption><title>Clinical isolate transcriptome analysis of genes differentially expressed in stationary phase <italic>in vitro hip</italic> mutants.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s029.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0155127.s030"><label>S25 Table</label><caption><title>Clinical isolate transcriptome analysis of genes upregulated (&#x0003e;4-fold) in H37Rv persister cells.</title><p>(TIF)</p></caption><media xlink:href="pone.0155127.s030.tif"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We sincerely thank all of the patients at National Masan Hospital who enrolled in the study and the clinical staff who supported the study; Dr. Eunjin Cho, Dr. Isdore Chola Shamputa, and Ying Cai for their help with the clinical isolates; Genome Sequencing Center for Infectious Disease at the Broad Institute, especially Dr. Jonathan Livny; Dr. Michael Chase for genome sequence annotation support; and Dr. Reddy Gali of Harvard Catalyst for help with microarray analysis.</p></ack><ref-list><title>References</title><ref id="pone.0155127.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Dye</surname><given-names>C</given-names></name>, <name><surname>Scheele</surname><given-names>S</given-names></name>, <name><surname>Dolin</surname><given-names>P</given-names></name>, <name><surname>Pathania</surname><given-names>V</given-names></name>, <name><surname>Raviglione</surname><given-names>MC</given-names></name>. <article-title>Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project</article-title>. <source>JAMA</source>. <year>1999</year>;<volume>282</volume>: <fpage>677</fpage>&#x02013;<lpage>686</lpage>. <?supplied-pmid 10517722?><pub-id pub-id-type="pmid">10517722</pub-id></mixed-citation></ref><ref id="pone.0155127.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>van Crevel</surname><given-names>R</given-names></name>, <name><surname>Ottenhoff</surname><given-names>TH</given-names></name>, <name><surname>van der Meer</surname><given-names>JW</given-names></name>. <article-title>Innate immunity to <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Clin Microbiol Rev</source>. <year>2002</year>;<volume>15</volume>: <fpage>294</fpage>&#x02013;<lpage>309</lpage>. <?supplied-pmid 11932234?><pub-id pub-id-type="pmid">11932234</pub-id></mixed-citation></ref><ref id="pone.0155127.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Parrish</surname><given-names>NM</given-names></name>, <name><surname>Dick</surname><given-names>JD</given-names></name>, <name><surname>Bishai</surname><given-names>WR</given-names></name>. <article-title>Mechanisms of latency in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Trends Microbiol</source>. <year>1998</year>;<volume>6</volume>: <fpage>107</fpage>&#x02013;<lpage>112</lpage>. <?supplied-pmid 9582936?><pub-id pub-id-type="pmid">9582936</pub-id></mixed-citation></ref><ref id="pone.0155127.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Wayne</surname><given-names>L</given-names></name>. <article-title>Dormancy of <italic>Mycobacterium tuberculosis</italic> and latency of disease</article-title>. <source>Eur J Clin Microbiol Infect Dis</source>. <year>1994</year>;<volume>13</volume>: <fpage>908</fpage>&#x02013;<lpage>914</lpage>. <?supplied-pmid 7698116?><pub-id pub-id-type="pmid">7698116</pub-id></mixed-citation></ref><ref id="pone.0155127.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Keren</surname><given-names>I</given-names></name>, <name><surname>Kaldalu</surname><given-names>N</given-names></name>, <name><surname>Spoering</surname><given-names>A</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Persister cells and tolerance to antimicrobials</article-title>. <source>FEMS Microbiol Lett</source>. <year>2004</year>;<volume>230</volume>: <fpage>13</fpage>&#x02013;<lpage>18</lpage>. <?supplied-pmid 14734160?><pub-id pub-id-type="pmid">14734160</pub-id></mixed-citation></ref><ref id="pone.0155127.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Balaban</surname><given-names>NQ</given-names></name>, <name><surname>Merrin</surname><given-names>J</given-names></name>, <name><surname>Chait</surname><given-names>R</given-names></name>, <name><surname>Kowalik</surname><given-names>L</given-names></name>, <name><surname>Leibler</surname><given-names>S</given-names></name>. <article-title>Bacterial Persistence as a Phenotypic Switch</article-title>. <source>Science</source>. <year>2004</year>;<volume>305</volume>: <fpage>1622</fpage>&#x02013;<lpage>1625</lpage>. <?supplied-pmid 15308767?><pub-id pub-id-type="pmid">15308767</pub-id></mixed-citation></ref><ref id="pone.0155127.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Keren</surname><given-names>I</given-names></name>, <name><surname>Shah</surname><given-names>D</given-names></name>, <name><surname>Spoering</surname><given-names>A</given-names></name>, <name><surname>Kaldalu</surname><given-names>N</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Specialized persister cells and the mechanism of multidrug tolerance in <italic>Escherichia coli</italic></article-title>. <source>J Bacteriol</source>. <year>2004</year>;<volume>186</volume>: <fpage>8172</fpage>&#x02013;<lpage>8180</lpage>. <?supplied-pmid 15576765?><pub-id pub-id-type="pmid">15576765</pub-id></mixed-citation></ref><ref id="pone.0155127.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Shah</surname><given-names>D</given-names></name>, <name><surname>Zhang</surname><given-names>Z</given-names></name>, <name><surname>Khodursky</surname><given-names>A</given-names></name>, <name><surname>Kaldalu</surname><given-names>N</given-names></name>, <name><surname>Kurg</surname><given-names>K</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Persisters: A distinct physiological state of <italic>E</italic>. <italic>coli</italic></article-title>. <source>BMC Microbiol</source>. <year>2006</year>;<volume>6</volume>: <fpage>53</fpage>&#x02013;<lpage>61</lpage>. <?supplied-pmid 16768798?><pub-id pub-id-type="pmid">16768798</pub-id></mixed-citation></ref><ref id="pone.0155127.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Maisonneuve</surname><given-names>E</given-names></name>, <name><surname>Shakespeare</surname><given-names>LJ</given-names></name>, <name><surname>Jorgensen</surname><given-names>MG</given-names></name>, <name><surname>Gerdes</surname><given-names>K</given-names></name>. <article-title>Bacterial persistence by RNA endonucleases</article-title>. <source>Proc Natl Acad Sci USA</source>. <year>2011</year>;<volume>108</volume>: <fpage>13206</fpage>&#x02013;<lpage>13211</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1100186108">10.1073/pnas.1100186108</ext-link></comment><?supplied-pmid 21788497?><pub-id pub-id-type="pmid">21788497</pub-id></mixed-citation></ref><ref id="pone.0155127.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Falla</surname><given-names>TJ</given-names></name>, <name><surname>Chopra</surname><given-names>I</given-names></name>. <article-title>Joint tolerance to beta-lactam and fluoroquinolone antibiotics in <italic>Escherichia coli</italic> results from overexpression of hipA</article-title>. <source>Antimicrob Agents Chemother</source>. <year>1998</year>;<volume>42</volume>: <fpage>3282</fpage>&#x02013;<lpage>3284</lpage>. <?supplied-pmid 9835528?><pub-id pub-id-type="pmid">9835528</pub-id></mixed-citation></ref><ref id="pone.0155127.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Schumacher</surname><given-names>MA</given-names></name>, <name><surname>Piro</surname><given-names>KM</given-names></name>, <name><surname>Xu</surname><given-names>W</given-names></name>, <name><surname>Hansen</surname><given-names>S</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>, <name><surname>Brennan</surname><given-names>RG</given-names></name>. <article-title>Molecular mechanisms of HipA-mediated multidrug tolerance and its neutralization by HipB</article-title>. <source>Science</source>. <year>2009</year>;<volume>323</volume>: <fpage>396</fpage>&#x02013;<lpage>401</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1163806">10.1126/science.1163806</ext-link></comment>
<?supplied-pmid 19150849?><pub-id pub-id-type="pmid">19150849</pub-id></mixed-citation></ref><ref id="pone.0155127.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Correia</surname><given-names>FF</given-names></name>, <name><surname>D&#x02019;Onofrio</surname><given-names>A</given-names></name>, <name><surname>Rejtar</surname><given-names>T</given-names></name>, <name><surname>Li</surname><given-names>L</given-names></name>, <name><surname>Karger</surname><given-names>BL</given-names></name>, <name><surname>Makarova</surname><given-names>K</given-names></name>, <etal>et al</etal>
<article-title>Kinase activity of overexpressed HipA is required for growth arrest and multidrug tolerance in <italic>Escherichia coli</italic></article-title>. <source>J Bacteriol</source>. <year>2006</year>;<volume>188</volume>: <fpage>8360</fpage>&#x02013;<lpage>8367</lpage>. <?supplied-pmid 17041039?><pub-id pub-id-type="pmid">17041039</pub-id></mixed-citation></ref><ref id="pone.0155127.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Harrison</surname><given-names>JJ</given-names></name>, <name><surname>Wade</surname><given-names>WD</given-names></name>, <name><surname>Akierman</surname><given-names>S</given-names></name>, <name><surname>Vacchi-Suzzi</surname><given-names>C</given-names></name>, <name><surname>Stremick</surname><given-names>CA</given-names></name>, <name><surname>Turner</surname><given-names>RJ</given-names></name>, <etal>et al</etal>
<article-title>The chromosomal toxin gene <italic>yafQ</italic> is a determinant of multidrug tolerance for <italic>Escherichia coli</italic> growing in a biofilm</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2009</year>;<volume>53</volume>: <fpage>2253</fpage>&#x02013;<lpage>2258</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00043-09">10.1128/AAC.00043-09</ext-link></comment>
<?supplied-pmid 19307375?><pub-id pub-id-type="pmid">19307375</pub-id></mixed-citation></ref><ref id="pone.0155127.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Maisonneuve</surname><given-names>E</given-names></name>, <name><surname>Castro-Camargo</surname><given-names>M</given-names></name>, <name><surname>Gerdes</surname><given-names>K</given-names></name>. <article-title>(p)ppGpp controls bacterial persistence by stochastic induction of toxin-antitoxin activity</article-title>. <source>Cell</source>. <year>2013</year>;<volume>154</volume>: <fpage>1140</fpage>&#x02013;<lpage>1150</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.cell.2013.07.048">10.1016/j.cell.2013.07.048</ext-link></comment>
<?supplied-pmid 23993101?><pub-id pub-id-type="pmid">23993101</pub-id></mixed-citation></ref><ref id="pone.0155127.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Dorr</surname><given-names>T</given-names></name>, <name><surname>Vulic</surname><given-names>M</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Ciprofloxacin causes persister formation by inducing the TisB toxin in <italic>Escherichia coli</italic></article-title>. <source>PLoS Biol</source>. <year>2010</year>;<volume>8</volume>: <fpage>e1000317</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pbio.1000317">10.1371/journal.pbio.1000317</ext-link></comment>
<?supplied-pmid 20186264?><pub-id pub-id-type="pmid">20186264</pub-id></mixed-citation></ref><ref id="pone.0155127.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Unoson</surname><given-names>C</given-names></name>, <name><surname>Wagner</surname><given-names>E</given-names></name>. <article-title>A small SOS-induced toxin is targeted against the inner membrane in <italic>Escherichia coli</italic></article-title>. <source>Mol Microbiol</source>. <year>2008</year>;<volume>70</volume>: <fpage>258</fpage>&#x02013;<lpage>270</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1365-2958.2008.06416.x">10.1111/j.1365-2958.2008.06416.x</ext-link></comment>
<?supplied-pmid 18761622?><pub-id pub-id-type="pmid">18761622</pub-id></mixed-citation></ref><ref id="pone.0155127.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Gurnev</surname><given-names>PA</given-names></name>, <name><surname>Ortenberg</surname><given-names>R</given-names></name>, <name><surname>Dorr</surname><given-names>T</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>, <name><surname>Bezrukov</surname><given-names>SM</given-names></name>. <article-title>Persister-promoting bacterial toxin TisB produces anion-selective pores in planar lipid bilayers</article-title>. <source>FEBS Lett</source>. <year>2012</year>;<volume>586</volume>: <fpage>2529</fpage>&#x02013;<lpage>2534</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.febslet.2012.06.021">10.1016/j.febslet.2012.06.021</ext-link></comment>
<?supplied-pmid 22728134?><pub-id pub-id-type="pmid">22728134</pub-id></mixed-citation></ref><ref id="pone.0155127.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Spoering</surname><given-names>A</given-names></name>, <name><surname>Vulic</surname><given-names>M</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>GlpD and PlsB participate in persister cell formation in <italic>Escherichia coli</italic></article-title>. <source>J Bacteriol</source>. <year>2006</year>;<volume>188</volume>: <fpage>5136</fpage>&#x02013;<lpage>5144</lpage>. <?supplied-pmid 16816185?><pub-id pub-id-type="pmid">16816185</pub-id></mixed-citation></ref><ref id="pone.0155127.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Hansen</surname><given-names>S</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>, <name><surname>Vulic</surname><given-names>M</given-names></name>. <article-title>Role of global regulators and nucleotide metabolism in antibiotic tolerance in <italic>Escherichia coli</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>2008</year>;<volume>52</volume>(<issue>8</issue>): <fpage>2718</fpage>&#x02013;<lpage>26</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00144-08">10.1128/AAC.00144-08</ext-link></comment>
<?supplied-pmid 18519731?><pub-id pub-id-type="pmid">18519731</pub-id></mixed-citation></ref><ref id="pone.0155127.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Girgis</surname><given-names>HS</given-names></name>, <name><surname>Harris</surname><given-names>K</given-names></name>, <name><surname>Tavazoie</surname><given-names>S</given-names></name>. <article-title>Large mutational target size for rapid emergence of bacterial persistence</article-title>. <source>PNAS</source>. <year>2012</year>;<volume>109</volume>: <fpage>12740</fpage>&#x02013;<lpage>12745</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.1205124109">10.1073/pnas.1205124109</ext-link></comment>
<?supplied-pmid 22802628?><pub-id pub-id-type="pmid">22802628</pub-id></mixed-citation></ref><ref id="pone.0155127.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Keren</surname><given-names>I</given-names></name>, <name><surname>Minami</surname><given-names>S</given-names></name>, <name><surname>Rubin</surname><given-names>E</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Characterization and transcriptome analysis of <italic>Mycobacterium tuberculosis</italic> persisters</article-title>. <source>MBio</source>. <year>2011</year>;<volume>2</volume>(<issue>3</issue>): <fpage>e00100</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/mBio.00100-11">10.1128/mBio.00100-11</ext-link></comment>
<?supplied-pmid 21673191?><pub-id pub-id-type="pmid">21673191</pub-id></mixed-citation></ref><ref id="pone.0155127.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Shao</surname><given-names>Y</given-names></name>, <name><surname>Harrison</surname><given-names>EM</given-names></name>, <name><surname>Bi</surname><given-names>D</given-names></name>, <name><surname>Tai</surname><given-names>C</given-names></name>, <name><surname>He</surname><given-names>X</given-names></name>, <name><surname>Ou</surname><given-names>HY</given-names></name>, <etal>et al</etal>
<article-title>TADB: a web-based resource for Type 2 toxin-antitoxin loci in bacteria and archaea</article-title>. <source>Nucleic Acids Res</source>. <year>2011</year>;<volume>39</volume>: <fpage>D606</fpage>&#x02013;<lpage>11</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkq908">10.1093/nar/gkq908</ext-link></comment>
<?supplied-pmid 20929871?><pub-id pub-id-type="pmid">20929871</pub-id></mixed-citation></ref><ref id="pone.0155127.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Sala</surname><given-names>A</given-names></name>, <name><surname>Bordes</surname><given-names>P</given-names></name>, <name><surname>Genevaux</surname><given-names>P</given-names></name>. <article-title>Multiple Toxin-Antitoxin Systems in Mycobacterium tuberculosis</article-title>. <source>Toxins</source>. <year>2014</year>;<volume>6</volume>(<issue>3</issue>): <fpage>1002</fpage>&#x02013;<lpage>1020</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3390/toxins6031002">10.3390/toxins6031002</ext-link></comment>
<?supplied-pmid 24662523?><pub-id pub-id-type="pmid">24662523</pub-id></mixed-citation></ref><ref id="pone.0155127.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Singh</surname><given-names>R</given-names></name>, <name><surname>Barry</surname><given-names>CE</given-names></name>, <name><surname>Boshoff</surname><given-names>HI</given-names></name>. <article-title>The three <italic>relE</italic> homologs of <italic>Mycobacterium tuberculosis</italic> have individual, drug-specific effects on bacterial antibiotic tolerance</article-title>. <source>J. Bacteriol</source>. <year>2010</year>;<volume>192</volume>: <fpage>1279</fpage>&#x02013;<lpage>1291</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.01285-09">10.1128/JB.01285-09</ext-link></comment>
<?supplied-pmid 20061486?><pub-id pub-id-type="pmid">20061486</pub-id></mixed-citation></ref><ref id="pone.0155127.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Aldridge</surname><given-names>BB</given-names></name>, <name><surname>Fernandez-Suarez</surname><given-names>M</given-names></name>, <name><surname>Heller</surname><given-names>D</given-names></name>, <name><surname>Ambravaneswaran</surname><given-names>V</given-names></name>, <name><surname>Irimia</surname><given-names>D</given-names></name>, <name><surname>Toner</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>Asymmetry and aging of mycobacterial cells lead to variable growth and antibiotic susceptibility</article-title>. <source>Science</source>. <year>2012</year>;<volume>335</volume>: <fpage>100</fpage>&#x02013;<lpage>104</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1216166">10.1126/science.1216166</ext-link></comment>
<?supplied-pmid 22174129?><pub-id pub-id-type="pmid">22174129</pub-id></mixed-citation></ref><ref id="pone.0155127.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Wakamoto</surname><given-names>Y</given-names></name>, <name><surname>Dhar</surname><given-names>N</given-names></name>, <name><surname>Chait</surname><given-names>R</given-names></name>, <name><surname>Schneider</surname><given-names>K</given-names></name>, <name><surname>Signorino-Gelo</surname><given-names>F</given-names></name>, <name><surname>Leibler</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Dynamic persistence of antibiotic-stressed mycobacteria</article-title>. <source>Science</source>. <year>2013</year>;<volume>339</volume>: <fpage>91</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1126/science.1229858">10.1126/science.1229858</ext-link></comment>
<?supplied-pmid 23288538?><pub-id pub-id-type="pmid">23288538</pub-id></mixed-citation></ref><ref id="pone.0155127.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Deb</surname><given-names>C</given-names></name>, <name><surname>Lee</surname><given-names>C-M</given-names></name>, <name><surname>Dubey</surname><given-names>VS</given-names></name>, <name><surname>Daniel</surname><given-names>J</given-names></name>, <name><surname>Abomoelak</surname><given-names>B</given-names></name>, <name><surname>Sirakova</surname><given-names>TD</given-names></name>, <etal>et al</etal>
<article-title>A Novel <italic>In Vitro</italic> Multiple-Stress Dormancy Model for <italic>Mycobacterium tuberculosis</italic> Generates a Lipid-Loaded, Drug-Tolerant, Dormant Pathogen</article-title>. <source>PLoS ONE</source>. <year>2009</year>;<volume>4</volume>: <fpage>e6077</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pone.0006077">10.1371/journal.pone.0006077</ext-link></comment>
<?supplied-pmid 19562030?><pub-id pub-id-type="pmid">19562030</pub-id></mixed-citation></ref><ref id="pone.0155127.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Baek</surname><given-names>S-H</given-names></name>, <name><surname>Li</surname><given-names>AH</given-names></name>, <name><surname>Sassetti</surname><given-names>CM</given-names></name>. <article-title>Metabolic regulation of mycobacterial growth and antibiotic sensitivity</article-title>. <source>PLoS Biol</source>. <year>2011</year>;<volume>9</volume>(<issue>5</issue>): <fpage>e1001065</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.pbio.1001065">10.1371/journal.pbio.1001065</ext-link></comment>
<?supplied-pmid 21629732?><pub-id pub-id-type="pmid">21629732</pub-id></mixed-citation></ref><ref id="pone.0155127.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Spoering</surname><given-names>AL</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Biofilms and planktonic cells of <italic>Pseudomonas aeruginosa</italic> have similar resistance to killing by antimicrobials</article-title>. <source>J Bacteriol</source>. <year>2001</year>;<volume>183</volume>: <fpage>6746</fpage>&#x02013;<lpage>6751</lpage>. <?supplied-pmid 11698361?><pub-id pub-id-type="pmid">11698361</pub-id></mixed-citation></ref><ref id="pone.0155127.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Moyed</surname><given-names>HS</given-names></name>, <name><surname>Bertrand</surname><given-names>KP</given-names></name>. <article-title>hipA, a newly recognized gene of <italic>Escherichia coli</italic> K-12 that affects frequency of persistence after inhibition of murein synthesis</article-title>. <source>J Bacteriol</source>. <year>1983</year>;<volume>155</volume>: <fpage>768</fpage>&#x02013;<lpage>775</lpage>. <?supplied-pmid 6348026?><pub-id pub-id-type="pmid">6348026</pub-id></mixed-citation></ref><ref id="pone.0155127.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Slattery</surname><given-names>A</given-names></name>, <name><surname>Victorsen</surname><given-names>AH</given-names></name>, <name><surname>Brown</surname><given-names>A</given-names></name>, <name><surname>Hillman</surname><given-names>K</given-names></name>, <name><surname>Phillips</surname><given-names>G</given-names></name>. <article-title>Isolation of Highly Persistent Mutants of <italic>Salmonella enterica</italic> Serovar Typhimurium Reveals a New Toxin-Antitoxin Module</article-title>. <source>J Bacteriol</source>. <year>2013</year>;<volume>195</volume>(<issue>4</issue>): <fpage>647</fpage>&#x02013;<lpage>657</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.01397-12">10.1128/JB.01397-12</ext-link></comment>
<?supplied-pmid 23204462?><pub-id pub-id-type="pmid">23204462</pub-id></mixed-citation></ref><ref id="pone.0155127.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>LaFleur</surname><given-names>MD</given-names></name>, <name><surname>Qi</surname><given-names>Q</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Patients with long-term oral carriage harbor high- persister mutants of <italic>Candida albicans</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>2010</year>;<volume>54</volume>: <fpage>39</fpage>&#x02013;<lpage>44</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/AAC.00860-09">10.1128/AAC.00860-09</ext-link></comment>
<?supplied-pmid 19841146?><pub-id pub-id-type="pmid">19841146</pub-id></mixed-citation></ref><ref id="pone.0155127.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Mulcahy</surname><given-names>LR</given-names></name>, <name><surname>Burns</surname><given-names>JL</given-names></name>, <name><surname>Lory</surname><given-names>S</given-names></name>, <name><surname>Lewis</surname><given-names>K</given-names></name>. <article-title>Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis</article-title>. <source>J Bacteriol</source>. <year>2010</year>;<volume>192</volume>: <fpage>6191</fpage>&#x02013;<lpage>6199</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1128/JB.01651-09">10.1128/JB.01651-09</ext-link></comment>
<?supplied-pmid 20935098?><pub-id pub-id-type="pmid">20935098</pub-id></mixed-citation></ref><ref id="pone.0155127.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Schumacher</surname><given-names>MA</given-names></name>, <name><surname>Balani</surname><given-names>P</given-names></name>, <name><surname>Min</surname><given-names>J</given-names></name>, <name><surname>Chinnam</surname><given-names>NB</given-names></name>, <name><surname>Hansen</surname><given-names>S</given-names></name>, <name><surname>Vuli&#x00107;</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>HipBA-promoter structures reveal the basis of heritable multidrug tolerance</article-title>. <source>Nature</source>. <year>2015</year>;<volume>524</volume>: <fpage>59</fpage>&#x02013;<lpage>64</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature14662">10.1038/nature14662</ext-link></comment>
<?supplied-pmid 26222023?><pub-id pub-id-type="pmid">26222023</pub-id></mixed-citation></ref><ref id="pone.0155127.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Sambandamurthy</surname><given-names>VK</given-names></name>, <name><surname>Derrick</surname><given-names>SC</given-names></name>, <name><surname>Jalapathy</surname><given-names>KV</given-names></name>, <name><surname>Chen</surname><given-names>B</given-names></name>, <name><surname>Russell</surname><given-names>RG</given-names></name>, <name><surname>Morris</surname><given-names>SL</given-names></name>, <etal>et al</etal>
<article-title>Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Infect Immun</source>. <year>2005</year>;<volume>73</volume>: <fpage>1196</fpage>&#x02013;<lpage>1203</lpage>. <?supplied-pmid 15664964?><pub-id pub-id-type="pmid">15664964</pub-id></mixed-citation></ref><ref id="pone.0155127.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Cox</surname><given-names>JS</given-names></name>, <name><surname>Chen</surname><given-names>B</given-names></name>, <name><surname>McNeil</surname><given-names>M</given-names></name>, <name><surname>Jacobs</surname><given-names>WR</given-names><suffix>Jr</suffix></name>. <article-title>Complex lipid determines tissue-specific replication of <italic>Mycobacterium tuberculosis</italic> in mice</article-title>. <source>Nature</source>. <year>1999</year>;<volume>402</volume>: <fpage>79</fpage>&#x02013;<lpage>83</lpage>. <?supplied-pmid 10573420?><pub-id pub-id-type="pmid">10573420</pub-id></mixed-citation></ref><ref id="pone.0155127.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Camacho</surname><given-names>LR</given-names></name>, <name><surname>Ensergueix</surname><given-names>D</given-names></name>, <name><surname>Perez</surname><given-names>E</given-names></name>, <name><surname>Gicquel</surname><given-names>B</given-names></name>, <name><surname>Guilhot</surname><given-names>C</given-names></name>. <article-title>Identification of a virulence gene cluster of <italic>Mycobacterium tuberculosis</italic> by signature-tagged transposon mutagenesis</article-title>. <source>Mol Microbiol</source>. <year>1999</year>;<volume>34</volume>: <fpage>257</fpage>&#x02013;<lpage>267</lpage>. <?supplied-pmid 10564470?><pub-id pub-id-type="pmid">10564470</pub-id></mixed-citation></ref><ref id="pone.0155127.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Murry</surname><given-names>JP</given-names></name>, <name><surname>Pandey</surname><given-names>AK</given-names></name>, <name><surname>Sassetti</surname><given-names>CM</given-names></name>, <name><surname>Rubin</surname><given-names>EJ</given-names></name>. <article-title>Phthiocerol dimycocerosate transport is required for resisting interferon-&#x003b3;&#x02013;independent immunity</article-title>. <source>J Infect Dis</source>. <year>2009</year>;<volume>200</volume>: <fpage>774</fpage>&#x02013;<lpage>782</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1086/605128">10.1086/605128</ext-link></comment>
<?supplied-pmid 19622047?><pub-id pub-id-type="pmid">19622047</pub-id></mixed-citation></ref><ref id="pone.0155127.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Nandakumar</surname><given-names>M</given-names></name>, <name><surname>Nathan</surname><given-names>C</given-names></name>, <name><surname>Rhee</surname><given-names>K</given-names></name>. <article-title>Isocitrate lyase mediates broad antibiotic tolerance in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Nature Comms</source>. <year>2013</year>;<volume>5</volume>: <fpage>4306</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/ncomms5306">10.1038/ncomms5306</ext-link></comment></mixed-citation></ref><ref id="pone.0155127.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Yokoyama</surname><given-names>K</given-names></name>, <name><surname>Ishijima</surname><given-names>SA</given-names></name>, <name><surname>Clowney</surname><given-names>L</given-names></name>, <name><surname>Koike</surname><given-names>H</given-names></name>, <name><surname>Aramaki</surname><given-names>H</given-names></name>, <name><surname>Tanaka</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Feast/famine regulatory proteins (FFRPs): <italic>Escherichia coli</italic> Lrp, AsnC and related archaeal transcription factors</article-title>. <source>FEMS Microbiol Rev</source>. <year>2006</year>;<volume>30</volume>: <fpage>89</fpage>&#x02013;<lpage>108</lpage>. <?supplied-pmid 16438681?><pub-id pub-id-type="pmid">16438681</pub-id></mixed-citation></ref><ref id="pone.0155127.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Alland</surname><given-names>D</given-names></name>, <name><surname>Steyn</surname><given-names>AJ</given-names></name>, <name><surname>Weisbrod</surname><given-names>T</given-names></name>, <name><surname>Aldrich</surname><given-names>K</given-names></name>, <name><surname>Jacobs</surname><given-names>WR</given-names><suffix>Jr</suffix></name>. <article-title>Characterization of the <italic>Mycobacterium tuberculosis</italic> iniBAC promoter, a promoter that responds to cell wall biosynthesis inhibition</article-title>. <source>J Bacteriol</source>. <year>2000</year>;<volume>182</volume>: <fpage>1802</fpage>&#x02013;<lpage>1811</lpage>. <?supplied-pmid 10714983?><pub-id pub-id-type="pmid">10714983</pub-id></mixed-citation></ref><ref id="pone.0155127.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Rastogi</surname><given-names>N</given-names></name>, <name><surname>Labrousse</surname><given-names>V</given-names></name>, and <name><surname>Goh</surname><given-names>KS</given-names></name>. <article-title>In Vitro Activities of Fourteen Antimicrobial Agents Against Drug Susceptible and Resistant Clinical Isolates of <italic>Mycobacterium tuberculosis</italic> and Comparative Intracellular Activities Against the Virulent H37Rv Strain in Human Macrophages</article-title>. <source>Curr Microbiol</source>. <year>1996</year>;<volume>33</volume>: <fpage>167</fpage>&#x02013;<lpage>175</lpage>. <?supplied-pmid 8672093?><pub-id pub-id-type="pmid">8672093</pub-id></mixed-citation></ref><ref id="pone.0155127.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Domenech</surname><given-names>P</given-names></name>, <name><surname>Reed</surname><given-names>MB</given-names></name>. <article-title>Rapid and spontaneous loss of phthiocerol dimycocerosate (PDIM) from <italic>Mycobacterium tuberculosis</italic> grown <italic>in vitro</italic>: implications for virulence studies</article-title>. <source>Mirobiol</source>. <year>2009</year>;<volume>155</volume>: <fpage>3532</fpage>&#x02013;<lpage>3543</lpage>.</mixed-citation></ref><ref id="pone.0155127.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Trivedi</surname><given-names>OA</given-names></name>, <name><surname>Arora</surname><given-names>P</given-names></name>, <name><surname>Vats</surname><given-names>A</given-names></name>, <name><surname>Ansari</surname><given-names>MZ</given-names></name>, <name><surname>Tickoo</surname><given-names>R</given-names></name>, <name><surname>Sridharan</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Dissecting the mechanism and assembly of a complex virulence mycobacterial lipid</article-title>. <source>Mol Cell</source>. <year>2005</year>;<volume>17</volume>: <fpage>631</fpage>&#x02013;<lpage>643</lpage>. <?supplied-pmid 15749014?><pub-id pub-id-type="pmid">15749014</pub-id></mixed-citation></ref><ref id="pone.0155127.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Amato</surname><given-names>SM</given-names></name>, <name><surname>Fazen</surname><given-names>CH</given-names></name>, <name><surname>Henry</surname><given-names>T</given-names></name>, <name><surname>Mok</surname><given-names>WW</given-names></name>, <name><surname>Orman</surname><given-names>MA</given-names></name>, <name><surname>Sandvik</surname><given-names>EL</given-names></name>, <etal>et al</etal>
<article-title>The role of metabolism in bacterial persistence</article-title>. <source>Front Microbiol</source>. <year>2014</year>;<volume>5</volume>: <fpage>70</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3389/fmicb.2014.00070">10.3389/fmicb.2014.00070</ext-link></comment>
<?supplied-pmid 24624123?><pub-id pub-id-type="pmid">24624123</pub-id></mixed-citation></ref><ref id="pone.0155127.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Walters</surname><given-names>SB</given-names></name>, <name><surname>Dubnau</surname><given-names>E</given-names></name>, <name><surname>Kolesnikova</surname><given-names>I</given-names></name>, <name><surname>Laval</surname><given-names>F</given-names></name>, <name><surname>Daffe</surname><given-names>M</given-names></name>, <name><surname>Smith</surname><given-names>I</given-names></name>. <article-title>The <italic>Mycobacterium tuberculosis</italic> PhoPR two-component system regulates genes essential for virulence and complex lipid biosynthesis</article-title>. <source>Mol Microbiol</source>. <year>2006</year>;<volume>60</volume>(<issue>2</issue>): <fpage>313</fpage>&#x02013;<lpage>330</lpage>.</mixed-citation></ref><ref id="pone.0155127.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Matsuura</surname><given-names>M</given-names></name>, <name><surname>Saldanha</surname><given-names>R</given-names></name>, <name><surname>Ma</surname><given-names>H</given-names></name>, <name><surname>Wank</surname><given-names>H</given-names></name>, <name><surname>Yang</surname><given-names>J</given-names></name>, <name><surname>Mohr</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>A bacterial group II intron encoding reverse transcriptase, maturase, and DNA endonuclease activities: biochemical demonstration of maturase activity and insertion of new genetic information within the intron</article-title>. <source>Genes Dev</source>. <year>1997</year>;<volume>11</volume>: <fpage>2910</fpage>&#x02013;<lpage>2924</lpage>
<?supplied-pmid 9353259?><pub-id pub-id-type="pmid">9353259</pub-id></mixed-citation></ref><ref id="pone.0155127.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Recchi</surname><given-names>C</given-names></name>, <name><surname>Sclavi</surname><given-names>B</given-names></name>, <name><surname>Rauzier</surname><given-names>J</given-names></name>, <name><surname>Gicquel</surname><given-names>B</given-names></name>, <name><surname>Reyrat</surname><given-names>JM</given-names></name>. <article-title>Mycobacterium tuberculosis Rv1395 is a class III transcriptional regulator of the AraC family involved in cytochrome P450 regulation</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>36</issue>): <fpage>33763</fpage>&#x02013;<lpage>73</lpage>. <?supplied-pmid 12826660?><pub-id pub-id-type="pmid">12826660</pub-id></mixed-citation></ref><ref id="pone.0155127.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Guo</surname><given-names>M</given-names></name>, <name><surname>Feng</surname><given-names>H</given-names></name>, <name><surname>Zhang</surname><given-names>J</given-names></name>, <name><surname>Wang</surname><given-names>W</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Dissecting transcription regulatory pathways through a new bacterial one-hybrid reporter system</article-title>. <source>Genome Res</source>. <year>2009</year>;<volume>9</volume>: <fpage>1301</fpage>&#x02013;<lpage>1308</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1101/gr.086595.108">10.1101/gr.086595.108</ext-link></comment><pub-id pub-id-type="pmid">19228590</pub-id></mixed-citation></ref><ref id="pone.0155127.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Wallis</surname><given-names>RS</given-names></name>, <name><surname>Patil</surname><given-names>S</given-names></name>, <name><surname>Cheon</surname><given-names>SH</given-names></name>, <name><surname>Edmonds</surname><given-names>K</given-names></name>, <name><surname>Phillips</surname><given-names>M</given-names></name>, <name><surname>Perkins</surname><given-names>MD</given-names></name>, <etal>et al</etal>
<article-title>Drug tolerance in <italic>Mycobacterium tuberculosis</italic></article-title>. <source>Antimicrob Agents Chemother</source>. <year>1999</year>;<volume>43</volume>: <fpage>2600</fpage>&#x02013;<lpage>2606</lpage>. <?supplied-pmid 10543735?><pub-id pub-id-type="pmid">10543735</pub-id></mixed-citation></ref><ref id="pone.0155127.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Pandy</surname><given-names>AK</given-names></name>, <name><surname>Sassetti</surname><given-names>CM</given-names></name>. <article-title>Mycobacterial persistence requires the utilization of host cholesterol</article-title>. <source>PNAS</source>. <year>2008</year>;<volume>105</volume>: <fpage>4376</fpage>&#x02013;<lpage>4380</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1073/pnas.0711159105">10.1073/pnas.0711159105</ext-link></comment>
<?supplied-pmid 18334639?><pub-id pub-id-type="pmid">18334639</pub-id></mixed-citation></ref><ref id="pone.0155127.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Andrews</surname><given-names>JM</given-names></name>. <article-title>Determination of minimum inhibitory concentrations</article-title>. <source>J Antimicrob Chemother</source>. <year>2001</year>;<volume>48</volume>: <fpage>5</fpage>&#x02013;<lpage>16</lpage>. <?supplied-pmid 11420333?><pub-id pub-id-type="pmid">11420333</pub-id></mixed-citation></ref><ref id="pone.0155127.ref053"><label>53</label><mixed-citation publication-type="book"><name><surname>Miller</surname><given-names>JH</given-names></name>. <source>A short course in bacterial genetics: a laboratory manual and handbook for <italic>Escherichia coli</italic> and related bacteria</source>. <volume>Vol 1</volume>
<publisher-loc>New York</publisher-loc>: <publisher-name>Cold Spring Harbor Laboratory Press</publisher-name>; <year>1992</year>.</mixed-citation></ref><ref id="pone.0155127.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Ehrt</surname><given-names>S</given-names></name>, <name><surname>Guo</surname><given-names>XV</given-names></name>, <name><surname>Hickey</surname><given-names>CM</given-names></name>, <name><surname>Ryou</surname><given-names>M</given-names></name>, <name><surname>Monteleone</surname><given-names>M</given-names></name>, <name><surname>Riley</surname><given-names>LW</given-names></name>, <etal>et al</etal>
<article-title>Controlling gene expression in mycobacteria with anhydrotetracycline and Tet repressor</article-title>. <source>Nucleic Acids Res</source>. <year>2005</year>;<volume>33</volume>(<issue>2</issue>): <fpage>e21</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gni013">10.1093/nar/gni013</ext-link></comment>
<?supplied-pmid 15687379?><pub-id pub-id-type="pmid">15687379</pub-id></mixed-citation></ref><ref id="pone.0155127.ref055"><label>55</label><mixed-citation publication-type="book"><name><surname>Neidhardt</surname><given-names>FC</given-names></name>, <name><surname>Ingraham</surname><given-names>JL</given-names></name>, <name><surname>Schaechter</surname><given-names>M</given-names></name>. <source>Physiology of the bacterial cell: a molecular approach</source>. <publisher-loc>Sunderland, MA</publisher-loc>: <publisher-name>Sinauer Associates</publisher-name>; <year>1990</year>.</mixed-citation></ref><ref id="pone.0155127.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Franzblau</surname><given-names>SG</given-names></name>, <name><surname>Witzig</surname><given-names>RS</given-names></name>, <name><surname>McLaughlin</surname><given-names>JC</given-names></name>, <name><surname>Torres</surname><given-names>P</given-names></name>, <name><surname>Madico</surname><given-names>G</given-names></name>, <name><surname>Hernandez</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Rapid, low-technology MIC determination with clinical <italic>Mycobacterium tuberculosis</italic> isolates by using the microplate Alamar Blue assay</article-title>. <source>J Clin Microbiol</source>. <year>1998</year>;<volume>36</volume>: <fpage>362</fpage>&#x02013;<lpage>366</lpage>. <?supplied-pmid 9466742?><pub-id pub-id-type="pmid">9466742</pub-id></mixed-citation></ref><ref id="pone.0155127.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Shell</surname><given-names>SS</given-names></name>, <name><surname>Prestwich</surname><given-names>EG</given-names></name>, <name><surname>Baek</surname><given-names>S-H</given-names></name>, <name><surname>Shah</surname><given-names>RR</given-names></name>, <name><surname>Sassetti</surname><given-names>CM</given-names></name>, <name><surname>Dedon</surname><given-names>PC</given-names></name>, <etal>et al</etal>
<article-title>DNA Methylation Impacts Gene Expression and Ensures Hypoxic Survival of <italic>Mycobacterium tuberculosis</italic></article-title>. <source>PLoS Pathog</source>. <year>2013</year>;<volume>9</volume>(<issue>7</issue>): <fpage>e1003419</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1371/journal.ppat.1003419">10.1371/journal.ppat.1003419</ext-link></comment>
<?supplied-pmid 23853579?><pub-id pub-id-type="pmid">23853579</pub-id></mixed-citation></ref><ref id="pone.0155127.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Bentley</surname><given-names>DR</given-names></name>, <name><surname>Balasubramanian</surname><given-names>S</given-names></name>, <name><surname>Swerdlow</surname><given-names>HP</given-names></name>, <name><surname>Smith</surname><given-names>GP</given-names></name>, <name><surname>Milton</surname><given-names>J</given-names></name>, <name><surname>Brown</surname><given-names>CG</given-names></name>, <etal>et al</etal>
<article-title>Accurate whole human genome sequencing using reversible termina- tor chemistry</article-title>. <source>Nature</source>. <year>2008</year>;<volume>456</volume>: <fpage>53</fpage>&#x02013;<lpage>59</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nature07517">10.1038/nature07517</ext-link></comment>
<?supplied-pmid 18987734?><pub-id pub-id-type="pmid">18987734</pub-id></mixed-citation></ref><ref id="pone.0155127.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Fisher</surname><given-names>S</given-names></name>, <name><surname>Barry</surname><given-names>A</given-names></name>, <name><surname>Abreu</surname><given-names>J</given-names></name>, <name><surname>Minie</surname><given-names>B</given-names></name>, <name><surname>Nolan</surname><given-names>J</given-names></name>, <name><surname>Delorey</surname><given-names>TM</given-names></name>, <etal>et al</etal>
<article-title>A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries</article-title>. <source>Genome Biol</source>. <year>2011</year>;<volume>12</volume>: <fpage>R1</fpage>
<?supplied-pmid 21205303?><pub-id pub-id-type="pmid">21205303</pub-id></mixed-citation></ref><ref id="pone.0155127.ref060"><label>60</label><mixed-citation publication-type="book">Calogero RA. oneChannelGUI: This package extends the capabilities of affyGUI interface. R Package Version 1.18.7. 2011; Available: <ext-link ext-link-type="uri" xlink:href="http://www.bioinformatica.unito.it/oneChannelGUI">http://www.bioinformatica.unito.it/oneChannelGUI</ext-link>.</mixed-citation></ref><ref id="pone.0155127.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Edgar</surname><given-names>R</given-names></name>, <name><surname>Domrachev</surname><given-names>M</given-names></name>, <name><surname>Lash</surname><given-names>AE</given-names></name>. <article-title>Gene Expression Omnibus: NCBI gene expression and hybridization array data repository</article-title>. <source>Nucleic Acids Res</source>. <year>2002</year>;<volume>30</volume>: <fpage>207</fpage>&#x02013;<lpage>210</lpage>. <?supplied-pmid 11752295?><pub-id pub-id-type="pmid">11752295</pub-id></mixed-citation></ref><ref id="pone.0155127.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Shishkin</surname><given-names>AA</given-names></name>, <name><surname>Giannoukos</surname><given-names>G</given-names></name>, <name><surname>Kucukural</surname><given-names>A</given-names></name>, <name><surname>Ciulla</surname><given-names>D</given-names></name>, <name><surname>Busby</surname><given-names>M</given-names></name>, <name><surname>Surka</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Simultaneous generation of many RNA-seq libraries in a single reaction</article-title>. <source>Nature Methods</source>. <year>2015</year>;<volume>12</volume>: <fpage>323</fpage>&#x02013;<lpage>325</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1038/nmeth.3313">10.1038/nmeth.3313</ext-link></comment>
<?supplied-pmid 25730492?><pub-id pub-id-type="pmid">25730492</pub-id></mixed-citation></ref><ref id="pone.0155127.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name>, <name><surname>Durbin</surname><given-names>R</given-names></name>. <article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title>. <source>Bioinformatics</source>. <year>2009</year>;<volume>25</volume>: <fpage>1754</fpage>&#x02013;<lpage>1760</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/bioinformatics/btp324">10.1093/bioinformatics/btp324</ext-link></comment>
<?supplied-pmid 19451168?><pub-id pub-id-type="pmid">19451168</pub-id></mixed-citation></ref><ref id="pone.0155127.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Gardner</surname><given-names>PP</given-names></name>, <name><surname>Daub</surname><given-names>J</given-names></name>, <name><surname>Tate</surname><given-names>JG</given-names></name>, <name><surname>Nawrocki</surname><given-names>EP</given-names></name>, <name><surname>Kolbe</surname><given-names>DL</given-names></name>, <name><surname>Lindgreen</surname><given-names>S</given-names></name>, <etal>et al</etal>
<article-title>Rfam: updates to the RNA families database</article-title>. <source>Nucleic Acids Res</source>. <year>2009</year>; <volume>37</volume>: <fpage>D136</fpage>&#x02013;<lpage>D140</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/nar/gkn766">10.1093/nar/gkn766</ext-link></comment>
<?supplied-pmid 18953034?><pub-id pub-id-type="pmid">18953034</pub-id></mixed-citation></ref><ref id="pone.0155127.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Mandlik</surname><given-names>A</given-names></name>, <name><surname>Livny</surname><given-names>J</given-names></name>, <name><surname>Robins</surname><given-names>WP</given-names></name>, <name><surname>Ritchie</surname><given-names>JM</given-names></name>, <name><surname>Mekalanos</surname><given-names>JJ</given-names></name>, <name><surname>Waldor</surname><given-names>MK</given-names></name>. <article-title>RNA-Seq-Based Monitoring of Infection-Linked Changes in <italic>Vibrio cholerae</italic> Gene Expression</article-title>. <source>Cell Host Microbe</source>. <year>2011</year>;<volume>10</volume>: <fpage>165</fpage>&#x02013;<lpage>174</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.chom.2011.07.007">10.1016/j.chom.2011.07.007</ext-link></comment>
<?supplied-pmid 21843873?><pub-id pub-id-type="pmid">21843873</pub-id></mixed-citation></ref><ref id="pone.0155127.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Anders</surname><given-names>S</given-names></name>, <name><surname>Huber</surname><given-names>W</given-names></name>. <article-title>Differential expression analysis for sequence count data</article-title>. <source>Genome Biol</source>. <year>2010</year>;<volume>11</volume>: <fpage>R106</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/gb-2010-11-10-r106">10.1186/gb-2010-11-10-r106</ext-link></comment>
<?supplied-pmid 20979621?><pub-id pub-id-type="pmid">20979621</pub-id></mixed-citation></ref></ref-list></back></article>